import type { Comparison, ComparisonCategory } from '@/lib/types'

export const comparisons: Comparison[] = [
  {
    slug: 'semaglutide-vs-tirzepatide',
    peptideA: 'semaglutide',
    peptideB: 'tirzepatide',
    title: 'Semaglutide vs Tirzepatide: Which GLP-1 Is Better for Weight Loss?',
    metaDescription: 'Compare semaglutide (Ozempic/Wegovy) vs tirzepatide (Mounjaro/Zepbound) for weight loss. Side-by-side analysis of effectiveness, side effects, cost, and availability.',
    winner: 'tirzepatide',
    keyTakeaway: 'Tirzepatide produces greater weight loss (20-26% vs 15-17%) thanks to dual GLP-1/GIP action, with potentially better tolerability. Semaglutide has a longer track record and more insurance coverage.',
    lastUpdated: '2026-02-15',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Weight Loss Efficacy', peptideAScore: '15-17%', peptideBScore: '20-26%', notes: 'Tirzepatide shows superior weight loss in SURMOUNT vs STEP trials (26.6% vs 16.9% at highest doses).', winner: 'B' },
      { name: 'Mechanism', peptideAScore: 'GLP-1 only', peptideBScore: 'GLP-1 + GIP dual', notes: 'Tirzepatide activates both GLP-1 and GIP receptors, providing dual incretin action.', winner: 'B' },
      { name: 'FDA Status', peptideAScore: 'Approved (obesity)', peptideBScore: 'Approved (obesity)', notes: 'Both FDA-approved for chronic weight management. Semaglutide as Wegovy, tirzepatide as Zepbound.', winner: 'tie' },
      { name: 'Nausea/GI Side Effects', peptideAScore: 'Moderate-High', peptideBScore: 'Moderate', notes: 'Both cause GI side effects. Some data suggests tirzepatide may be slightly better tolerated.', winner: 'B' },
      { name: 'Dosing Frequency', peptideAScore: 'Weekly', peptideBScore: 'Weekly', notes: 'Both administered as once-weekly subcutaneous injections.', winner: 'tie' },
      { name: 'Monthly Cost', peptideAScore: '$1,000-1,350', peptideBScore: '$1,000-1,100', notes: 'Brand-name costs similar. Compounded versions vary widely ($150-500/month).', winner: 'tie' },
      { name: 'Insurance Coverage', peptideAScore: 'Moderate', peptideBScore: 'Growing', notes: 'Semaglutide has longer track record with insurers. Tirzepatide coverage expanding rapidly.', winner: 'A' },
      { name: 'Muscle Preservation', peptideAScore: 'Poor', peptideBScore: 'Slightly Better', notes: 'Both cause lean mass loss. Tirzepatide may preserve slightly more muscle due to GIP action.', winner: 'B' },
    ],
    verdicts: [
      {
        peptide: 'Semaglutide',
        heading: 'Choose Semaglutide if...',
        reasons: [
          'You need the most proven, well-documented option with years of post-market data',
          'Your insurance covers Wegovy or Ozempic but not Zepbound',
          'You want the largest body of long-term safety data available',
          'You prefer a medication with extensive cardiovascular outcome data (SELECT trial)',
        ],
      },
      {
        peptide: 'Tirzepatide',
        heading: 'Choose Tirzepatide if...',
        reasons: [
          'Maximum weight loss is your primary goal (20-26% vs 15-17%)',
          'You want potentially fewer GI side effects during titration',
          'Muscle preservation matters to you (GIP receptor may help)',
          'You can access it through insurance or compounding pharmacy',
        ],
      },
    ],
    citations: [
      { authors: 'Jastreboff AM, Aronne LJ, et al.', title: 'Tirzepatide Once Weekly for the Treatment of Obesity', journal: 'N Engl J Med', year: 2022, pmid: '35658024', keyFinding: 'SURMOUNT-1: Tirzepatide achieved 20.9% (10mg) and 22.5% (15mg) weight loss at 72 weeks.' },
      { authors: 'Wilding JPH, Batterham RL, et al.', title: 'Once-Weekly Semaglutide in Adults with Overweight or Obesity', journal: 'N Engl J Med', year: 2021, pmid: '33567185', keyFinding: 'STEP 1: Semaglutide 2.4mg achieved 14.9% weight loss at 68 weeks vs 2.4% placebo.' },
      { authors: 'Lincoff AM, Brown-Frandsen K, et al.', title: 'Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes', journal: 'N Engl J Med', year: 2023, pmid: '37952131', keyFinding: 'SELECT trial: Semaglutide reduced major cardiovascular events by 20% in people with obesity.' },
      { authors: 'Frias JP, Davies MJ, et al.', title: 'Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes', journal: 'N Engl J Med', year: 2021, pmid: '34170647', keyFinding: 'SURPASS-2: Tirzepatide superior to semaglutide 1mg for A1C reduction and weight loss in T2D.' },
    ],
    faqs: [
      { question: 'Is tirzepatide really better than semaglutide for weight loss?', answer: 'Clinical trial data shows tirzepatide produces greater average weight loss (20-26% vs 15-17% body weight). However, individual responses vary significantly. Some people respond better to semaglutide. The best choice depends on your specific health profile, insurance coverage, and how you tolerate each medication.' },
      { question: 'Can I switch from semaglutide to tirzepatide?', answer: 'Yes, switching is possible under medical supervision. Most doctors recommend completing your current titration schedule, then starting the new medication at the lowest dose. There is no required washout period, but your doctor will determine the best transition plan for your situation.' },
      { question: 'Are the side effects different?', answer: 'Both cause similar GI side effects (nausea, diarrhea, constipation), especially during dose titration. Some studies suggest tirzepatide may cause slightly less nausea at equivalent efficacy levels, possibly due to the GIP receptor component, but more head-to-head data is needed.' },
      { question: 'Which is cheaper — semaglutide or tirzepatide?', answer: 'Brand-name costs are similar ($1,000-1,350/month). Compounded semaglutide is currently more widely available and often cheaper ($150-400/month) due to the ongoing FDA shortage designation. Compounded tirzepatide availability and pricing vary by pharmacy.' },
      { question: 'What about long-term safety?', answer: 'Semaglutide has more long-term safety data since it was approved earlier and has the large SELECT cardiovascular outcomes trial. Tirzepatide safety data is growing rapidly with its expanding clinical trial program. Both are considered safe when used as prescribed.' },
    ],
    relatedComparisons: ['semaglutide-vs-retatrutide', 'tirzepatide-vs-retatrutide', 'semaglutide-vs-tirzepatide-vs-retatrutide', 'ozempic-vs-wegovy'],
  },
  {
    slug: 'semaglutide-vs-retatrutide',
    peptideA: 'semaglutide',
    peptideB: 'retatrutide',
    title: 'Semaglutide vs Retatrutide: Single vs Triple Agonist Compared',
    metaDescription: 'Compare semaglutide (GLP-1) vs retatrutide (triple agonist GLP-1/GIP/glucagon). Effectiveness, research status, and what the Phase 2 data shows.',
    keyTakeaway: 'Retatrutide shows comparable or superior weight loss to semaglutide with triple receptor action, but remains in clinical trials. Semaglutide is the proven, available option today.',
    lastUpdated: '2026-01-20',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Weight Loss Efficacy', peptideAScore: '15-17%', peptideBScore: '24-26%', notes: 'Retatrutide Phase 2 data showed up to 24.2% weight loss at 48 weeks. Still awaiting Phase 3 results.', winner: 'B' },
      { name: 'Mechanism', peptideAScore: 'GLP-1 only', peptideBScore: 'GLP-1 + GIP + Glucagon', notes: 'Retatrutide is a triple agonist — the glucagon receptor adds thermogenic fat burning.', winner: 'B' },
      { name: 'FDA Status', peptideAScore: 'Approved', peptideBScore: 'Phase 3 trials', notes: 'Semaglutide is FDA-approved. Retatrutide is still in clinical trials (Phase 3 ongoing).', winner: 'A' },
      { name: 'Side Effects', peptideAScore: 'Well-documented', peptideBScore: 'Limited data', notes: 'Semaglutide has years of post-market safety data. Retatrutide safety profile still being established.', winner: 'A' },
      { name: 'Availability', peptideAScore: 'Widely available', peptideBScore: 'Research only', notes: 'Semaglutide available by prescription. Retatrutide only through clinical trials or research suppliers.', winner: 'A' },
      { name: 'Cost', peptideAScore: '$150-1,350/mo', peptideBScore: '$200-400/mo (research)', notes: 'Semaglutide ranges from compounded to brand. Retatrutide only available from research peptide vendors.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'Semaglutide',
        heading: 'Choose Semaglutide if...',
        reasons: [
          'You want an FDA-approved medication with extensive safety data',
          'Availability and insurance coverage matter to you',
          'You prefer a proven track record over bleeding-edge potential',
        ],
      },
      {
        peptide: 'Retatrutide',
        heading: 'Consider Retatrutide if...',
        reasons: [
          'You are in a clinical trial or have access to research-grade peptides',
          'Maximum weight loss potential is your priority and you accept the unknown risk profile',
          'You are interested in the added liver/metabolic benefits of glucagon receptor activation',
        ],
      },
    ],
    citations: [
      { authors: 'Jastreboff AM, Kaplan LM, et al.', title: 'Triple-Hormone-Receptor Agonist Retatrutide for Obesity', journal: 'N Engl J Med', year: 2023, pmid: '37385337', keyFinding: 'Phase 2: Retatrutide achieved up to 24.2% weight loss at 48 weeks at the highest dose.' },
      { authors: 'Wilding JPH, Batterham RL, et al.', title: 'Once-Weekly Semaglutide in Adults with Overweight or Obesity', journal: 'N Engl J Med', year: 2021, pmid: '33567185', keyFinding: 'STEP 1: Semaglutide 2.4mg achieved 14.9% weight loss at 68 weeks.' },
    ],
    faqs: [
      { question: 'When will retatrutide be FDA-approved?', answer: 'Retatrutide is currently in Phase 3 clinical trials. If results are positive, FDA approval could come in 2027-2028. Timelines are subject to change based on trial outcomes and regulatory review.' },
      { question: 'Is retatrutide safer than semaglutide?', answer: 'We do not have enough data to make that comparison yet. Semaglutide has years of post-market safety data across millions of patients. Retatrutide Phase 2 data showed a similar side effect profile, but Phase 3 and long-term data are still needed.' },
      { question: 'Can I get retatrutide from a compounding pharmacy?', answer: 'Retatrutide is not currently available from legitimate compounding pharmacies. It is only available through clinical trials or research peptide suppliers, which are not regulated for human use.' },
    ],
    relatedComparisons: ['semaglutide-vs-tirzepatide', 'tirzepatide-vs-retatrutide', 'semaglutide-vs-tirzepatide-vs-retatrutide'],
  },
  {
    slug: 'tirzepatide-vs-retatrutide',
    peptideA: 'tirzepatide',
    peptideB: 'retatrutide',
    title: 'Tirzepatide vs Retatrutide: Dual vs Triple Agonist for Weight Loss',
    metaDescription: 'Compare tirzepatide (dual GLP-1/GIP) vs retatrutide (triple GLP-1/GIP/glucagon). Which next-gen peptide offers more weight loss potential?',
    keyTakeaway: 'Tirzepatide and retatrutide show similar peak weight loss, but retatrutide adds glucagon receptor activation for enhanced liver benefits. Tirzepatide is available now; retatrutide is still in trials.',
    lastUpdated: '2026-01-20',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Weight Loss Efficacy', peptideAScore: '20-26%', peptideBScore: '24-26%', notes: 'Both show similar peak weight loss. Retatrutide Phase 2 data comparable to tirzepatide SURMOUNT results.', winner: 'tie' },
      { name: 'Mechanism', peptideAScore: 'GLP-1 + GIP', peptideBScore: 'GLP-1 + GIP + Glucagon', notes: 'Retatrutide adds glucagon receptor activation for enhanced thermogenesis and lipid metabolism.', winner: 'B' },
      { name: 'FDA Status', peptideAScore: 'Approved', peptideBScore: 'Phase 3 trials', notes: 'Tirzepatide FDA-approved. Retatrutide expected to complete Phase 3 trials by 2026-2027.', winner: 'A' },
      { name: 'MASH/Liver Benefits', peptideAScore: 'Moderate', peptideBScore: 'Strong signal', notes: 'Retatrutide showed significant liver fat reduction in trials — glucagon receptor may drive hepatic benefits.', winner: 'B' },
      { name: 'Dosing', peptideAScore: 'Weekly', peptideBScore: 'Weekly', notes: 'Both once-weekly subcutaneous injections.', winner: 'tie' },
      { name: 'Availability', peptideAScore: 'Prescription', peptideBScore: 'Research only', notes: 'Tirzepatide widely available. Retatrutide limited to trials and research suppliers.', winner: 'A' },
    ],
    verdicts: [
      {
        peptide: 'Tirzepatide',
        heading: 'Choose Tirzepatide if...',
        reasons: [
          'You want a proven, FDA-approved medication available today',
          'Weight loss is your primary goal and you want strong clinical evidence',
          'You prefer the security of established post-market safety data',
        ],
      },
      {
        peptide: 'Retatrutide',
        heading: 'Consider Retatrutide if...',
        reasons: [
          'You have fatty liver disease (MASH/NAFLD) and want maximum hepatic benefit',
          'You have access through clinical trials',
          'You want the potential metabolic advantages of triple receptor activation',
        ],
      },
    ],
    citations: [
      { authors: 'Jastreboff AM, Kaplan LM, et al.', title: 'Triple-Hormone-Receptor Agonist Retatrutide for Obesity', journal: 'N Engl J Med', year: 2023, pmid: '37385337', keyFinding: 'Phase 2: Up to 24.2% weight loss at 48 weeks with significant liver fat reduction.' },
      { authors: 'Jastreboff AM, Aronne LJ, et al.', title: 'Tirzepatide Once Weekly for the Treatment of Obesity', journal: 'N Engl J Med', year: 2022, pmid: '35658024', keyFinding: 'SURMOUNT-1: 22.5% weight loss at highest dose over 72 weeks.' },
    ],
    faqs: [
      { question: 'Is retatrutide better than tirzepatide?', answer: 'In Phase 2 data, retatrutide and tirzepatide showed similar peak weight loss. Retatrutide may offer additional liver benefits from glucagon receptor activation. However, Phase 3 data for retatrutide is still pending, so a definitive comparison is premature.' },
      { question: 'Will retatrutide replace tirzepatide?', answer: 'Unlikely. They will probably coexist as options. Some patients may respond better to one or the other, and tirzepatide already has a massive established user base and safety record.' },
    ],
    relatedComparisons: ['semaglutide-vs-tirzepatide', 'semaglutide-vs-retatrutide', 'semaglutide-vs-tirzepatide-vs-retatrutide'],
  },
  {
    slug: 'semaglutide-vs-liraglutide',
    peptideA: 'semaglutide',
    peptideB: 'liraglutide',
    title: 'Semaglutide vs Liraglutide: Weekly vs Daily GLP-1 for Weight Loss',
    metaDescription: 'Compare semaglutide (Wegovy, weekly) vs liraglutide (Saxenda, daily) for weight loss. Efficacy, convenience, side effects, and cost breakdown.',
    winner: 'semaglutide',
    keyTakeaway: 'Semaglutide produces roughly double the weight loss of liraglutide (15-17% vs 5-8%) with the convenience of weekly instead of daily dosing. Liraglutide has a longer safety record.',
    lastUpdated: '2026-01-10',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Weight Loss Efficacy', peptideAScore: '15-17%', peptideBScore: '5-8%', notes: 'Semaglutide produces roughly double the weight loss of liraglutide in clinical trials.', winner: 'A' },
      { name: 'Dosing Frequency', peptideAScore: 'Once weekly', peptideBScore: 'Once daily', notes: 'Semaglutide offers significantly better convenience with weekly vs daily injections.', winner: 'A' },
      { name: 'FDA Status', peptideAScore: 'Approved', peptideBScore: 'Approved', notes: 'Both FDA-approved for chronic weight management (Wegovy and Saxenda respectively).', winner: 'tie' },
      { name: 'Side Effects', peptideAScore: 'Moderate-High GI', peptideBScore: 'Moderate GI', notes: 'Both cause nausea and GI effects. Semaglutide may have slightly higher rates due to potency.', winner: 'B' },
      { name: 'Monthly Cost', peptideAScore: '$1,000-1,350', peptideBScore: '$1,000-1,350', notes: 'Brand-name costs similar. Both have compounded alternatives at lower price points.', winner: 'tie' },
      { name: 'Track Record', peptideAScore: 'Newer (2021)', peptideBScore: 'Longer (2014)', notes: 'Liraglutide has longer post-market safety data. Both have strong clinical evidence bases.', winner: 'B' },
    ],
    verdicts: [
      {
        peptide: 'Semaglutide',
        heading: 'Choose Semaglutide if...',
        reasons: [
          'Maximum weight loss is your priority',
          'You want the convenience of once-weekly dosing',
          'You want cardiovascular outcome data (SELECT trial)',
        ],
      },
      {
        peptide: 'Liraglutide',
        heading: 'Choose Liraglutide if...',
        reasons: [
          'You prefer the longest available safety record',
          'GI side effects are a major concern (slightly milder profile)',
          'Your insurance covers Saxenda but not Wegovy',
        ],
      },
    ],
    citations: [
      { authors: 'Rubino DM, Greenway FL, et al.', title: 'Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes', journal: 'JAMA', year: 2022, pmid: '35015037', keyFinding: 'STEP 8: Direct comparison showed semaglutide 2.4mg achieved 15.8% weight loss vs 6.4% for liraglutide 3.0mg.' },
    ],
    faqs: [
      { question: 'Is semaglutide just a newer version of liraglutide?', answer: 'Both are GLP-1 receptor agonists, but semaglutide has structural modifications that give it a longer half-life (weekly vs daily dosing) and greater potency. They activate the same receptor through similar mechanisms.' },
      { question: 'Can I switch from liraglutide to semaglutide?', answer: 'Yes, switching is common and straightforward under medical supervision. Your doctor will typically start semaglutide at the lowest dose after stopping liraglutide.' },
    ],
    relatedComparisons: ['semaglutide-vs-tirzepatide', 'ozempic-vs-wegovy', 'semaglutide-vs-survodutide'],
  },
  {
    slug: 'bpc-157-vs-tb-500',
    peptideA: 'bpc-157',
    peptideB: 'tb-500',
    title: 'BPC-157 vs TB-500: Which Healing Peptide Is Better?',
    metaDescription: 'Compare BPC-157 vs TB-500 (thymosin beta-4) for injury recovery and healing. Mechanisms, dosing, research evidence, and which to choose for your goals.',
    keyTakeaway: 'BPC-157 excels at gut and localized tissue healing with oral bioavailability. TB-500 is better for systemic tissue repair and cardiac healing. They are most effective when stacked together.',
    lastUpdated: '2026-02-01',
    category: 'healing-recovery',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Primary Use', peptideAScore: 'Gut + tendon healing', peptideBScore: 'Systemic tissue repair', notes: 'BPC-157 excels at gut and localized injuries. TB-500 better for systemic and cardiac tissue repair.', winner: 'tie' },
      { name: 'Mechanism', peptideAScore: 'Angiogenesis + GH receptor upregulation', peptideBScore: 'Actin regulation + cell migration', notes: 'Different mechanisms — often used together for complementary healing pathways.', winner: 'tie' },
      { name: 'Research Level', peptideAScore: 'Moderate (mostly animal)', peptideBScore: 'Moderate (mostly animal)', notes: 'Both have extensive animal data but limited human clinical trials.', winner: 'tie' },
      { name: 'Administration', peptideAScore: 'SubQ or oral', peptideBScore: 'SubQ only', notes: 'BPC-157 has oral bioavailability (especially for gut issues). TB-500 requires injection.', winner: 'A' },
      { name: 'Typical Duration', peptideAScore: '4-6 weeks', peptideBScore: '4-8 weeks', notes: 'Both run in short cycles. Loading phase common with TB-500.', winner: 'tie' },
      { name: 'FDA Status', peptideAScore: 'Research only', peptideBScore: 'Research only', notes: 'Neither is FDA-approved. Both available from research peptide suppliers.', winner: 'tie' },
      { name: 'Side Effects', peptideAScore: 'Minimal reported', peptideBScore: 'Minimal reported', notes: 'Both considered well-tolerated based on available data. Head rush occasionally reported with TB-500.', winner: 'tie' },
      { name: 'Cost', peptideAScore: '$30-60/vial', peptideBScore: '$40-80/vial', notes: 'Both affordable. TB-500 slightly more expensive due to higher dosing requirements.', winner: 'A' },
    ],
    verdicts: [
      {
        peptide: 'BPC-157',
        heading: 'Choose BPC-157 if...',
        reasons: [
          'Your injury is gut-related (IBS, leaky gut, ulcers)',
          'You want the option of oral dosing (no injections)',
          'You have a localized tendon, ligament, or joint injury',
          'Budget is a concern (cheaper per cycle)',
        ],
      },
      {
        peptide: 'TB-500',
        heading: 'Choose TB-500 if...',
        reasons: [
          'You need systemic tissue repair across multiple areas',
          'You have a cardiac or cardiovascular healing goal',
          'Your injury involves muscle tissue or large wound areas',
          'You want enhanced flexibility and reduced inflammation system-wide',
        ],
      },
    ],
    citations: [
      { authors: 'Sikiric P, Rucman R, et al.', title: 'Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications', journal: 'Curr Neuropharmacol', year: 2016, pmid: '26830964', keyFinding: 'Comprehensive review of BPC-157 mechanisms across gut-brain axis, angiogenesis, and tissue repair pathways.' },
      { authors: 'Sosne G, Qiu P, et al.', title: 'Thymosin beta 4 and the eye: I can see clearly now the pain is gone', journal: 'Ann N Y Acad Sci', year: 2012, pmid: '23130423', keyFinding: 'TB-500 (thymosin beta-4) promotes wound healing through actin regulation, cell migration, and anti-inflammatory pathways.' },
    ],
    faqs: [
      { question: 'Can I take BPC-157 and TB-500 together?', answer: 'Yes, stacking BPC-157 and TB-500 is the most common approach in the peptide community. They work through complementary mechanisms — BPC-157 promotes angiogenesis and growth factor upregulation while TB-500 regulates actin and cell migration. Many users report faster recovery with the combination.' },
      { question: 'Which is better for tendon injuries?', answer: 'BPC-157 is generally considered superior for tendon and ligament injuries due to its specific mechanism of promoting tendon-to-bone healing and growth hormone receptor upregulation in tendons. TB-500 supports the process through broader tissue repair mechanisms.' },
      { question: 'Are these peptides legal?', answer: 'Neither BPC-157 nor TB-500 is FDA-approved for human use. They are available as research peptides. Legality varies by jurisdiction. In the US, they can be purchased for research purposes. Consult local regulations before purchasing.' },
    ],
    relatedComparisons: ['ghk-cu-vs-bpc-157', 'bpc-157-vs-ghk-cu', 'pentadecapeptide-bpc-157-vs-ghk-cu-vs-tb-500'],
  },
  {
    slug: 'ipamorelin-vs-cjc-1295',
    peptideA: 'ipamorelin',
    peptideB: 'cjc-1295',
    title: 'Ipamorelin vs CJC-1295: Growth Hormone Peptides Compared',
    metaDescription: 'Compare ipamorelin (GHRP) vs CJC-1295 (GHRH) for growth hormone release. How they work together, dosing protocols, and why they are commonly stacked.',
    keyTakeaway: 'Ipamorelin and CJC-1295 work through different GH pathways and are most commonly used together. Ipamorelin creates natural GH pulses; CJC-1295 sustains elevated GH levels.',
    lastUpdated: '2026-01-15',
    category: 'gh-secretagogue',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Mechanism', peptideAScore: 'GHRP (ghrelin mimetic)', peptideBScore: 'GHRH analog', notes: 'Ipamorelin stimulates GH release via ghrelin receptor. CJC-1295 amplifies natural GHRH signaling.', winner: 'tie' },
      { name: 'GH Release Pattern', peptideAScore: 'Pulsatile (sharp spikes)', peptideBScore: 'Sustained elevation', notes: 'Ipamorelin creates natural-like GH pulses. CJC-1295 (with DAC) extends GH elevation for days.', winner: 'tie' },
      { name: 'Cortisol Impact', peptideAScore: 'No increase', peptideBScore: 'No increase', notes: 'Neither raises cortisol or prolactin — a key advantage over other GH secretagogues like GHRP-6.', winner: 'tie' },
      { name: 'Best For', peptideAScore: 'Sleep + recovery', peptideBScore: 'Sustained GH levels', notes: 'Ipamorelin best pre-bed for sleep quality. CJC-1295 for consistent GH elevation.', winner: 'tie' },
      { name: 'Dosing Frequency', peptideAScore: '2-3x daily', peptideBScore: '1-2x daily (no DAC) or 2x/week (with DAC)', notes: 'CJC-1295 with DAC needs less frequent dosing due to extended half-life.', winner: 'B' },
      { name: 'Synergy', peptideAScore: 'Best with CJC-1295', peptideBScore: 'Best with Ipamorelin', notes: 'These two are the most commonly stacked GH peptides — GHRP + GHRH = amplified GH release.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'Ipamorelin',
        heading: 'Choose Ipamorelin alone if...',
        reasons: [
          'Sleep quality and recovery are your primary goals',
          'You want the most selective GHRP with no cortisol or prolactin increase',
          'You are new to GH peptides and want a gentle starting point',
        ],
      },
      {
        peptide: 'CJC-1295',
        heading: 'Choose CJC-1295 alone if...',
        reasons: [
          'You want sustained GH elevation rather than acute pulses',
          'Less frequent dosing matters (with DAC variant)',
          'Your goal is body composition changes over time rather than acute recovery',
        ],
      },
    ],
    citations: [
      { authors: 'Raun K, Hansen BS, et al.', title: 'Ipamorelin, the first selective growth hormone secretagogue', journal: 'Eur J Endocrinol', year: 1998, pmid: '9784065', keyFinding: 'Ipamorelin selectively stimulates GH release without affecting cortisol, prolactin, or ACTH levels.' },
      { authors: 'Teichman SL, Neale A, et al.', title: 'Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295', journal: 'J Clin Endocrinol Metab', year: 2006, pmid: '16352683', keyFinding: 'CJC-1295 with DAC produced sustained GH and IGF-1 elevation for 6-14 days after a single dose.' },
    ],
    faqs: [
      { question: 'Should I use ipamorelin and CJC-1295 together?', answer: 'Most practitioners recommend stacking them. Ipamorelin (GHRP) and CJC-1295 (GHRH) stimulate growth hormone through complementary pathways. Together, they produce a synergistic GH release that is greater than either alone. This is the most popular GH peptide stack.' },
      { question: 'What is the difference between CJC-1295 with and without DAC?', answer: 'DAC (Drug Affinity Complex) extends the half-life of CJC-1295 from about 30 minutes to 6-8 days. CJC-1295 without DAC (also called Modified GRF 1-29) requires daily dosing but produces more natural GH pulsing. With DAC requires only 2x/week dosing but maintains constant GH elevation.' },
      { question: 'When should I take these peptides?', answer: 'Ipamorelin is most commonly taken before bed to enhance the natural nighttime GH pulse and improve sleep quality. CJC-1295 without DAC is typically dosed morning and evening. CJC-1295 with DAC is dosed 2x per week at any time.' },
    ],
    relatedComparisons: ['ipamorelin-cjc-1295-vs-mk-677', 'tesamorelin-vs-ipamorelin', 'sermorelin-vs-ipamorelin'],
  },
  {
    slug: 'semaglutide-vs-survodutide',
    peptideA: 'semaglutide',
    peptideB: 'survodutide',
    title: 'Semaglutide vs Survodutide: GLP-1 vs GLP-1/Glucagon Dual Agonist',
    metaDescription: 'Compare semaglutide vs survodutide for weight loss and MASH treatment. How the GLP-1/glucagon dual mechanism differs from GLP-1 alone.',
    keyTakeaway: 'Survodutide shows slightly higher weight loss plus strong liver benefits from glucagon receptor activation, but remains in Phase 3 trials. Semaglutide is the proven choice available now.',
    lastUpdated: '2026-01-20',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Weight Loss', peptideAScore: '15-17%', peptideBScore: '18-19%', notes: 'Survodutide Phase 2 showed up to 18.7% weight loss at 46 weeks.', winner: 'B' },
      { name: 'Mechanism', peptideAScore: 'GLP-1 only', peptideBScore: 'GLP-1 + Glucagon', notes: 'Survodutide adds glucagon for enhanced hepatic fat metabolism and thermogenesis.', winner: 'B' },
      { name: 'FDA Status', peptideAScore: 'Approved', peptideBScore: 'Phase 3 trials', notes: 'Semaglutide approved. Survodutide in Phase 3 for obesity and MASH.', winner: 'A' },
      { name: 'Liver Benefits', peptideAScore: 'Moderate', peptideBScore: 'Strong', notes: 'Survodutide shows significant MASH resolution — glucagon receptor drives liver fat reduction.', winner: 'B' },
      { name: 'Side Effects', peptideAScore: 'Well-documented', peptideBScore: 'Limited data', notes: 'GI effects expected with both. Survodutide safety profile still being characterized.', winner: 'A' },
    ],
    verdicts: [
      {
        peptide: 'Semaglutide',
        heading: 'Choose Semaglutide if...',
        reasons: [
          'You want a proven, available medication today',
          'Weight loss without liver disease is your goal',
          'You value extensive long-term safety data',
        ],
      },
      {
        peptide: 'Survodutide',
        heading: 'Watch Survodutide if...',
        reasons: [
          'You have fatty liver disease (MASH/NAFLD)',
          'You want the potential of glucagon-mediated fat burning',
          'You are willing to wait for FDA approval or join a clinical trial',
        ],
      },
    ],
    citations: [
      { authors: 'Blüher M, Rosenstock J, et al.', title: 'Survodutide Phase 2 results in obesity', journal: 'Lancet', year: 2024, keyFinding: 'Survodutide achieved up to 18.7% weight loss at 46 weeks with significant liver fat reduction.' },
    ],
    faqs: [
      { question: 'Is survodutide better than semaglutide for fatty liver?', answer: 'Early data suggests yes. Survodutide glucagon receptor activation directly targets liver fat metabolism. It is being developed specifically for both obesity and MASH (metabolic dysfunction-associated steatohepatitis). Semaglutide also reduces liver fat, but survodutide appears to do so more aggressively.' },
    ],
    relatedComparisons: ['semaglutide-vs-tirzepatide', 'semaglutide-vs-retatrutide', 'tirzepatide-vs-retatrutide'],
  },
  {
    slug: 'ozempic-vs-wegovy',
    peptideA: 'semaglutide',
    peptideB: 'semaglutide',
    title: 'Ozempic vs Wegovy: Same Drug, Different Doses — What You Need to Know',
    metaDescription: 'Ozempic and Wegovy are both semaglutide. Learn the key differences in dosing, FDA approval, insurance coverage, and which one is prescribed for weight loss.',
    keyTakeaway: 'Ozempic and Wegovy contain identical semaglutide. The difference is FDA indication (diabetes vs obesity), max dose (2.0mg vs 2.4mg), and insurance coverage pathways.',
    lastUpdated: '2026-02-10',
    category: 'brand-vs-brand',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Active Ingredient', peptideAScore: 'Semaglutide', peptideBScore: 'Semaglutide', notes: 'Identical molecule. The difference is dose, indication, and branding.', winner: 'tie' },
      { name: 'FDA Indication', peptideAScore: 'Type 2 Diabetes', peptideBScore: 'Chronic Weight Management', notes: 'Ozempic approved for T2D. Wegovy approved for obesity/overweight with comorbidity.', winner: 'tie' },
      { name: 'Max Dose', peptideAScore: '2.0 mg/week', peptideBScore: '2.4 mg/week', notes: 'Wegovy goes to a higher maintenance dose specifically optimized for weight loss.', winner: 'B' },
      { name: 'Insurance', peptideAScore: 'Better T2D coverage', peptideBScore: 'Weight loss coverage varies', notes: 'Ozempic often easier to get covered for diabetes. Wegovy coverage for obesity improving but inconsistent.', winner: 'A' },
      { name: 'Off-Label Use', peptideAScore: 'Common for weight loss', peptideBScore: 'N/A (on-label)', notes: 'Many get Ozempic prescribed off-label for weight loss due to better insurance coverage.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'Ozempic',
        heading: 'Choose Ozempic if...',
        reasons: [
          'You have Type 2 diabetes (on-label use)',
          'Your insurance covers Ozempic but not Wegovy',
          'Your doctor recommends it for off-label weight management',
        ],
      },
      {
        peptide: 'Wegovy',
        heading: 'Choose Wegovy if...',
        reasons: [
          'Weight loss is your primary goal (higher max dose at 2.4mg)',
          'You want the on-label indication for obesity',
          'Your insurance covers anti-obesity medications',
        ],
      },
    ],
    citations: [
      { authors: 'Novo Nordisk', title: 'Ozempic (semaglutide) Prescribing Information', journal: 'FDA Label', year: 2024, keyFinding: 'Ozempic approved for T2D at doses 0.5mg, 1.0mg, and 2.0mg weekly.' },
      { authors: 'Novo Nordisk', title: 'Wegovy (semaglutide) Prescribing Information', journal: 'FDA Label', year: 2024, keyFinding: 'Wegovy approved for chronic weight management at 2.4mg weekly maintenance dose.' },
    ],
    faqs: [
      { question: 'Are Ozempic and Wegovy the same thing?', answer: 'Yes and no. They contain the same active ingredient (semaglutide) made by the same company (Novo Nordisk). The differences are the FDA-approved indication, maximum dose, and how insurance categorizes them. Wegovy goes up to 2.4mg for weight loss; Ozempic maxes at 2.0mg for diabetes.' },
      { question: 'Can I use Ozempic for weight loss?', answer: 'Many doctors prescribe Ozempic off-label for weight loss, especially when insurance does not cover Wegovy. This is legal and common, but your doctor needs to determine if it is appropriate for your situation.' },
      { question: 'Which has better insurance coverage?', answer: 'It depends on your plan. Ozempic generally has better coverage when prescribed for diabetes. Wegovy coverage for weight loss is expanding but varies significantly by insurer. Some plans cover neither for weight loss.' },
    ],
    relatedComparisons: ['semaglutide-vs-tirzepatide', 'mounjaro-vs-zepbound', 'compounded-vs-brand-semaglutide'],
  },
  {
    slug: 'mounjaro-vs-zepbound',
    peptideA: 'tirzepatide',
    peptideB: 'tirzepatide',
    title: 'Mounjaro vs Zepbound: Same Drug, Different Labels Explained',
    metaDescription: 'Mounjaro and Zepbound are both tirzepatide. Compare FDA approvals, dosing, insurance, and which brand name to ask your doctor about for weight loss.',
    keyTakeaway: 'Mounjaro and Zepbound are identical tirzepatide. Mounjaro is labeled for Type 2 diabetes; Zepbound is labeled for obesity. Insurance coverage determines which most people get.',
    lastUpdated: '2026-02-10',
    category: 'brand-vs-brand',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Active Ingredient', peptideAScore: 'Tirzepatide', peptideBScore: 'Tirzepatide', notes: 'Same molecule. Different brand names for different indications.', winner: 'tie' },
      { name: 'FDA Indication', peptideAScore: 'Type 2 Diabetes', peptideBScore: 'Chronic Weight Management', notes: 'Mounjaro for T2D. Zepbound for obesity/overweight.', winner: 'tie' },
      { name: 'Max Dose', peptideAScore: '15 mg/week', peptideBScore: '15 mg/week', notes: 'Same dose range for both brands.', winner: 'tie' },
      { name: 'Insurance', peptideAScore: 'Better T2D coverage', peptideBScore: 'Weight loss coverage growing', notes: 'Mounjaro often easier for insurance. Zepbound weight management coverage expanding.', winner: 'A' },
    ],
    verdicts: [
      {
        peptide: 'Mounjaro',
        heading: 'Choose Mounjaro if...',
        reasons: [
          'You have Type 2 diabetes',
          'Your insurance covers Mounjaro but not Zepbound',
        ],
      },
      {
        peptide: 'Zepbound',
        heading: 'Choose Zepbound if...',
        reasons: [
          'Weight loss is your primary indication',
          'Your insurance covers anti-obesity medications',
        ],
      },
    ],
    citations: [
      { authors: 'Eli Lilly', title: 'Mounjaro (tirzepatide) Prescribing Information', journal: 'FDA Label', year: 2024, keyFinding: 'Mounjaro approved for T2D at doses 2.5mg to 15mg weekly.' },
      { authors: 'Eli Lilly', title: 'Zepbound (tirzepatide) Prescribing Information', journal: 'FDA Label', year: 2024, keyFinding: 'Zepbound approved for chronic weight management at doses up to 15mg weekly.' },
    ],
    faqs: [
      { question: 'Is Mounjaro the same as Zepbound?', answer: 'Yes, both contain tirzepatide made by Eli Lilly. The only differences are the brand name, FDA indication, and insurance coverage pathway. The medication itself is identical.' },
    ],
    relatedComparisons: ['ozempic-vs-wegovy', 'semaglutide-vs-tirzepatide', 'compounded-vs-brand-semaglutide'],
  },
  {
    slug: 'ghk-cu-vs-bpc-157',
    peptideA: 'ghk-cu',
    peptideB: 'bpc-157',
    title: 'GHK-Cu vs BPC-157: Anti-Aging vs Healing Peptides',
    metaDescription: 'Compare GHK-Cu (copper peptide for skin and anti-aging) vs BPC-157 (body protection compound for healing). Different uses, mechanisms, and when to use each.',
    keyTakeaway: 'GHK-Cu is primarily an anti-aging and skin rejuvenation peptide with unique topical applications. BPC-157 is a healing-focused peptide for internal tissue repair. Different goals, different peptides.',
    lastUpdated: '2026-01-15',
    category: 'cross-category',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Primary Use', peptideAScore: 'Skin/anti-aging', peptideBScore: 'Injury healing', notes: 'GHK-Cu excels at skin rejuvenation and collagen synthesis. BPC-157 targets internal tissue repair.', winner: 'tie' },
      { name: 'Mechanism', peptideAScore: 'Copper delivery + gene modulation', peptideBScore: 'Angiogenesis + growth factor upregulation', notes: 'Different pathways — GHK-Cu modulates 4,000+ genes. BPC-157 promotes blood vessel growth and tissue repair.', winner: 'tie' },
      { name: 'Administration', peptideAScore: 'Topical, SubQ, or IV', peptideBScore: 'SubQ or oral', notes: 'GHK-Cu uniquely effective as topical application for skin. BPC-157 has oral bioavailability.', winner: 'tie' },
      { name: 'Research Level', peptideAScore: 'Moderate', peptideBScore: 'Moderate', notes: 'Both have solid preclinical data. GHK-Cu has more human skin studies; BPC-157 more animal healing studies.', winner: 'tie' },
      { name: 'Side Effects', peptideAScore: 'Very mild', peptideBScore: 'Very mild', notes: 'Both well-tolerated. GHK-Cu topical has essentially zero systemic side effects.', winner: 'tie' },
      { name: 'Cost', peptideAScore: '$25-60/vial', peptideBScore: '$30-60/vial', notes: 'Similar pricing. GHK-Cu topical serums can be more expensive from cosmetic brands.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'GHK-Cu',
        heading: 'Choose GHK-Cu if...',
        reasons: [
          'Your primary goal is skin health, wrinkles, or anti-aging',
          'You want a topical option (no injections needed)',
          'You are interested in hair growth or wound healing on the skin surface',
        ],
      },
      {
        peptide: 'BPC-157',
        heading: 'Choose BPC-157 if...',
        reasons: [
          'You have an internal injury (gut, tendon, ligament, muscle)',
          'You want oral dosing for gut healing',
          'Your goal is tissue repair rather than cosmetic anti-aging',
        ],
      },
    ],
    citations: [
      { authors: 'Pickart L, Vasquez-Soltero JM, Margolina A.', title: 'GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration', journal: 'Biomed Res Int', year: 2015, pmid: '25861625', keyFinding: 'GHK-Cu modulates expression of 4,000+ human genes, promoting tissue remodeling and anti-inflammatory responses.' },
    ],
    faqs: [
      { question: 'Can I use GHK-Cu and BPC-157 together?', answer: 'Yes. They target different systems and have no known interactions. GHK-Cu for skin/anti-aging and BPC-157 for internal healing can be used concurrently.' },
    ],
    relatedComparisons: ['bpc-157-vs-tb-500', 'ghk-cu-vs-epitalon', 'pentadecapeptide-bpc-157-vs-ghk-cu-vs-tb-500'],
  },
  {
    slug: 'semaglutide-vs-tirzepatide-vs-retatrutide',
    peptideA: 'semaglutide',
    peptideB: 'tirzepatide',
    peptideC: 'retatrutide',
    title: 'Semaglutide vs Tirzepatide vs Retatrutide: Complete GLP-1 Comparison',
    metaDescription: 'The ultimate GLP-1 comparison: semaglutide (single), tirzepatide (dual), and retatrutide (triple agonist). Weight loss data, mechanisms, availability, and cost.',
    keyTakeaway: 'Each generation adds receptor activation: semaglutide (GLP-1), tirzepatide (GLP-1+GIP), retatrutide (GLP-1+GIP+glucagon). More receptors correlate with more weight loss, but less safety data.',
    lastUpdated: '2026-01-20',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Weight Loss', peptideAScore: '15-17%', peptideBScore: '20-26%', peptideCScore: '24-26%', notes: 'Progressive improvement from single to triple agonist. Retatrutide Phase 2 data rivals tirzepatide.', winner: 'B' },
      { name: 'Receptors', peptideAScore: 'GLP-1', peptideBScore: 'GLP-1 + GIP', peptideCScore: 'GLP-1 + GIP + Glucagon', notes: 'Each generation adds a receptor. More receptors = more metabolic pathways activated.', winner: 'C' },
      { name: 'FDA Status', peptideAScore: 'Approved', peptideBScore: 'Approved', peptideCScore: 'Phase 3', notes: 'Semaglutide and tirzepatide available now. Retatrutide expected 2026-2027.', winner: 'tie' },
      { name: 'Safety Data', peptideAScore: 'Extensive', peptideBScore: 'Growing', peptideCScore: 'Limited', notes: 'Safety confidence inversely correlated with novelty. Semaglutide has most post-market data.', winner: 'A' },
      { name: 'Cost (Brand)', peptideAScore: '$1,000+/mo', peptideBScore: '$1,000+/mo', peptideCScore: 'N/A', notes: 'Brand-name GLP-1s are expensive. Retatrutide not yet commercially available.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'Semaglutide',
        heading: 'Choose Semaglutide if...',
        reasons: ['You want the most proven option with the most safety data', 'Insurance coverage is a priority', 'You want cardiovascular outcome evidence (SELECT trial)'],
      },
      {
        peptide: 'Tirzepatide',
        heading: 'Choose Tirzepatide if...',
        reasons: ['Maximum currently-available weight loss matters most', 'You want dual receptor action with growing safety data', 'You can access it (insurance or compounding)'],
      },
      {
        peptide: 'Retatrutide',
        heading: 'Consider Retatrutide if...',
        reasons: ['You have access through clinical trials', 'Liver health is a major concern', 'You are willing to accept limited safety data for cutting-edge potential'],
      },
    ],
    citations: [
      { authors: 'Jastreboff AM, Kaplan LM, et al.', title: 'Triple-Hormone-Receptor Agonist Retatrutide for Obesity', journal: 'N Engl J Med', year: 2023, pmid: '37385337', keyFinding: 'Phase 2: Retatrutide achieved up to 24.2% weight loss at 48 weeks.' },
      { authors: 'Jastreboff AM, Aronne LJ, et al.', title: 'Tirzepatide Once Weekly for the Treatment of Obesity', journal: 'N Engl J Med', year: 2022, pmid: '35658024', keyFinding: 'SURMOUNT-1: 22.5% weight loss at highest dose.' },
      { authors: 'Wilding JPH, Batterham RL, et al.', title: 'Once-Weekly Semaglutide in Adults with Overweight or Obesity', journal: 'N Engl J Med', year: 2021, pmid: '33567185', keyFinding: 'STEP 1: 14.9% weight loss at 68 weeks.' },
    ],
    faqs: [
      { question: 'Which GLP-1 agonist should I start with?', answer: 'Most doctors start patients with semaglutide or tirzepatide since both are FDA-approved and available. The choice typically depends on insurance coverage and individual health factors. Retatrutide is not yet available outside clinical trials.' },
      { question: 'Will there be even more advanced versions?', answer: 'Yes. Multiple companies are developing quad-agonists and other multi-receptor combinations. The incretin field is advancing rapidly, with several new candidates in clinical trials.' },
    ],
    relatedComparisons: ['semaglutide-vs-tirzepatide', 'semaglutide-vs-retatrutide', 'tirzepatide-vs-retatrutide'],
  },
  {
    slug: 'ipamorelin-cjc-1295-vs-mk-677',
    peptideA: 'ipamorelin',
    peptideB: 'mk-677',
    title: 'Ipamorelin + CJC-1295 vs MK-677: GH Peptides vs Oral Secretagogue',
    metaDescription: 'Compare injectable ipamorelin/CJC-1295 stack vs oral MK-677 (ibutamoren) for growth hormone. Effectiveness, side effects, convenience, and cost.',
    keyTakeaway: 'Ipamorelin/CJC-1295 produces cleaner, more natural GH pulsing with fewer side effects. MK-677 offers oral convenience and lower cost but causes hunger and water retention.',
    lastUpdated: '2026-01-15',
    category: 'gh-secretagogue',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Administration', peptideAScore: 'SubQ injection', peptideBScore: 'Oral capsule', notes: 'MK-677 is oral — major convenience advantage. Ipamorelin/CJC requires daily injections.', winner: 'B' },
      { name: 'GH Elevation', peptideAScore: 'Pulsatile (natural pattern)', peptideBScore: 'Sustained 24hr elevation', notes: 'Ipamorelin/CJC mimics natural GH pulses. MK-677 raises GH and IGF-1 continuously.', winner: 'A' },
      { name: 'Hunger Effects', peptideAScore: 'Minimal', peptideBScore: 'Significant increase', notes: 'MK-677 strongly increases appetite via ghrelin pathway. Can be problematic for weight loss goals.', winner: 'A' },
      { name: 'Water Retention', peptideAScore: 'Minimal', peptideBScore: 'Moderate-High', notes: 'MK-677 commonly causes water retention and bloating, especially initially.', winner: 'A' },
      { name: 'Sleep Quality', peptideAScore: 'Improved', peptideBScore: 'Improved', notes: 'Both enhance sleep quality through GH elevation. Often cited as a primary benefit.', winner: 'tie' },
      { name: 'Cost', peptideAScore: '$80-150/mo (stack)', peptideBScore: '$30-60/mo', notes: 'MK-677 significantly cheaper and no reconstitution needed.', winner: 'B' },
      { name: 'Blood Sugar', peptideAScore: 'Neutral', peptideBScore: 'May increase', notes: 'MK-677 can raise fasting blood glucose. Ipamorelin/CJC stack is blood sugar neutral.', winner: 'A' },
    ],
    verdicts: [
      {
        peptide: 'Ipamorelin + CJC-1295',
        heading: 'Choose Ipamorelin/CJC-1295 if...',
        reasons: [
          'You want cleaner GH release with minimal side effects',
          'Blood sugar management matters (diabetes risk)',
          'You are trying to lose weight (no hunger increase)',
          'You are comfortable with injections',
        ],
      },
      {
        peptide: 'MK-677',
        heading: 'Choose MK-677 if...',
        reasons: [
          'You want the simplicity of oral dosing',
          'Budget is a major factor',
          'Appetite increase is a feature, not a bug (underweight/bulking)',
          'You want to avoid injections entirely',
        ],
      },
    ],
    citations: [
      { authors: 'Nass R, Pezzoli SS, et al.', title: 'Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults', journal: 'Ann Intern Med', year: 2008, pmid: '18838728', keyFinding: 'MK-677 increased GH and IGF-1 levels in older adults with improved body composition over 2 years.' },
    ],
    faqs: [
      { question: 'Which produces more growth hormone?', answer: 'MK-677 produces sustained 24-hour GH elevation, which may result in higher total daily GH output. However, ipamorelin/CJC-1295 produces a more natural pulsatile pattern that better mimics youthful GH secretion. Quality of GH release pattern may matter more than total quantity.' },
      { question: 'Can I combine MK-677 with ipamorelin/CJC-1295?', answer: 'Some people do combine them, but this significantly increases GH and IGF-1 levels and may increase side effect risk. This should only be considered with medical supervision and blood work monitoring.' },
    ],
    relatedComparisons: ['ipamorelin-vs-cjc-1295', 'tesamorelin-vs-ipamorelin', 'sermorelin-vs-ipamorelin'],
  },
  {
    slug: 'compounded-vs-brand-semaglutide',
    peptideA: 'semaglutide',
    peptideB: 'semaglutide',
    title: 'Compounded vs Brand-Name Semaglutide: Price, Safety, and Legality',
    metaDescription: 'Compare compounded semaglutide ($150-500/mo) vs brand-name Ozempic/Wegovy ($1,000+/mo). Is compounded semaglutide safe, legal, and effective?',
    keyTakeaway: 'Compounded semaglutide costs 60-85% less than brand-name. It is legal under FDA shortage rules and can be effective, but quality varies by pharmacy. 503B facilities offer the highest quality compounding.',
    lastUpdated: '2026-02-20',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Cost', peptideAScore: '$1,000-1,350/mo', peptideBScore: '$150-500/mo', notes: 'Compounded semaglutide is 60-85% cheaper. Price varies by pharmacy and source.', winner: 'B' },
      { name: 'FDA Oversight', peptideAScore: 'Full FDA approval', peptideBScore: '503A/503B compounding', notes: 'Brand-name is fully FDA-regulated. Compounded is legal under FDA shortage rules but less regulated.', winner: 'A' },
      { name: 'Purity/Testing', peptideAScore: 'Pharmaceutical grade', peptideBScore: 'Varies by pharmacy', notes: 'Brand-name guaranteed pure. Compounded quality depends on the pharmacy — 503B facilities have stricter standards.', winner: 'A' },
      { name: 'Availability', peptideAScore: 'Supply shortages', peptideBScore: 'Generally available', notes: 'Brand-name semaglutide has had persistent shortages. Compounding pharmacies fill the gap.', winner: 'B' },
      { name: 'Insurance', peptideAScore: 'Sometimes covered', peptideBScore: 'Rarely covered', notes: 'Brand-name may be covered by insurance. Compounded is typically cash-pay only.', winner: 'A' },
      { name: 'Legal Status', peptideAScore: 'Standard Rx', peptideBScore: 'Legal during shortage', notes: 'Compounded semaglutide is legal while FDA shortage designation is active. Status may change.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'Brand-Name Semaglutide',
        heading: 'Choose Brand-Name if...',
        reasons: [
          'Your insurance covers Ozempic or Wegovy',
          'You want guaranteed pharmaceutical-grade purity',
          'You prefer full FDA regulatory oversight',
        ],
      },
      {
        peptide: 'Compounded Semaglutide',
        heading: 'Choose Compounded if...',
        reasons: [
          'Cost is a barrier (saving $500-1,000+/month)',
          'Brand-name is unavailable due to shortages',
          'You choose a reputable 503B outsourcing facility',
          'You are comfortable with the current legal framework',
        ],
      },
    ],
    citations: [
      { authors: 'FDA', title: 'FDA Drug Shortage Database: Semaglutide', journal: 'FDA.gov', year: 2024, keyFinding: 'Semaglutide products have been listed on the FDA drug shortage list since 2022, enabling compounding under federal law.' },
      { authors: 'Novo Nordisk', title: 'Semaglutide (Wegovy) Prescribing Information', journal: 'FDA Label', year: 2024, keyFinding: 'Wegovy (semaglutide 2.4mg) approved for chronic weight management with proven efficacy and safety profile.' },
    ],
    faqs: [
      { question: 'Is compounded semaglutide safe?', answer: 'Safety depends heavily on the pharmacy. 503B outsourcing facilities operate under stricter FDA oversight with batch testing requirements. 503A pharmacies (traditional compounding) have less oversight. Always verify your pharmacy is licensed and uses third-party testing.' },
      { question: 'What happens when the shortage ends?', answer: 'When the FDA shortage designation is removed, compounding pharmacies will have a transition period to stop producing semaglutide. Patients would need to switch to brand-name or find alternative treatments. The timeline for shortage resolution is uncertain.' },
      { question: 'Is compounded semaglutide as effective?', answer: 'When properly compounded, semaglutide is the same molecule regardless of source. The key variable is purity and accurate dosing, which depends on pharmacy quality. Reports from patients and clinics suggest comparable results when sourced from reputable 503B facilities.' },
    ],
    relatedComparisons: ['ozempic-vs-wegovy', 'semaglutide-vs-tirzepatide', 'semaglutide-vs-liraglutide'],
  },
  {
    slug: 'mots-c-vs-aod-9604',
    peptideA: 'mots-c',
    peptideB: 'aod-9604',
    title: 'MOTS-c vs AOD-9604: Metabolic Peptides for Fat Loss Compared',
    metaDescription: 'Compare MOTS-c (mitochondrial peptide) vs AOD-9604 (HGH fragment) for fat loss. Different mechanisms, research evidence, and which fits your goals.',
    keyTakeaway: 'MOTS-c is a broader metabolic optimizer that acts as an exercise mimetic. AOD-9604 is a targeted fat-loss fragment of growth hormone. Different mechanisms for different goals.',
    lastUpdated: '2026-01-10',
    category: 'metabolic',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Mechanism', peptideAScore: 'Mitochondrial metabolic regulation', peptideBScore: 'Lipolysis (HGH fragment 176-191)', notes: 'MOTS-c activates AMPK and improves cellular metabolism. AOD-9604 mimics the fat-burning portion of growth hormone.', winner: 'tie' },
      { name: 'Weight Loss Evidence', peptideAScore: 'Preliminary (strong animal data)', peptideBScore: 'Moderate', notes: 'AOD-9604 has more direct fat loss studies. MOTS-c research focuses on metabolic function broadly.', winner: 'B' },
      { name: 'Additional Benefits', peptideAScore: 'Exercise mimetic, insulin sensitivity', peptideBScore: 'Targeted fat reduction', notes: 'MOTS-c acts as an exercise mimetic. AOD-9604 is more narrowly focused on fat metabolism.', winner: 'A' },
      { name: 'Side Effects', peptideAScore: 'Minimal reported', peptideBScore: 'Minimal reported', notes: 'Both well-tolerated in available data.', winner: 'tie' },
      { name: 'FDA Status', peptideAScore: 'Research only', peptideBScore: 'Research only', notes: 'Neither is FDA-approved for any indication.', winner: 'tie' },
      { name: 'Cost', peptideAScore: '$60-120/vial', peptideBScore: '$30-50/vial', notes: 'MOTS-c tends to be more expensive due to synthesis complexity.', winner: 'B' },
    ],
    verdicts: [
      {
        peptide: 'MOTS-c',
        heading: 'Choose MOTS-c if...',
        reasons: [
          'You want broader metabolic benefits beyond just fat loss',
          'Insulin sensitivity and mitochondrial health are priorities',
          'You want an "exercise mimetic" effect',
        ],
      },
      {
        peptide: 'AOD-9604',
        heading: 'Choose AOD-9604 if...',
        reasons: [
          'Targeted fat loss is your primary goal',
          'Budget matters (significantly cheaper)',
          'You want a more studied compound for fat metabolism specifically',
        ],
      },
    ],
    citations: [
      { authors: 'Lee C, Zeng J, et al.', title: 'The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance', journal: 'Cell Metab', year: 2015, pmid: '25738459', keyFinding: 'MOTS-c regulates metabolic homeostasis through AMPK activation, acting as an exercise mimetic.' },
    ],
    faqs: [
      { question: 'Can I stack MOTS-c with AOD-9604?', answer: 'Yes, some users combine them for complementary fat loss mechanisms. MOTS-c for metabolic optimization and AOD-9604 for targeted lipolysis. No known contraindications between the two.' },
    ],
    relatedComparisons: ['aod-9604-vs-semaglutide', 'semaglutide-vs-tirzepatide'],
  },
  {
    slug: 'tesamorelin-vs-ipamorelin',
    peptideA: 'tesamorelin',
    peptideB: 'ipamorelin',
    title: 'Tesamorelin vs Ipamorelin: Which GH Peptide Is Right for You?',
    metaDescription: 'Compare tesamorelin (FDA-approved GHRH analog) vs ipamorelin (GHRP). Mechanisms, fat loss evidence, side effects, and availability.',
    winner: 'tesamorelin',
    keyTakeaway: 'Tesamorelin is the only FDA-approved GH peptide with strong visceral fat reduction data. Ipamorelin is cheaper and more accessible but lacks the clinical evidence base.',
    lastUpdated: '2026-01-15',
    category: 'gh-secretagogue',
    hasEditorialContent: true,
    dimensions: [
      { name: 'FDA Status', peptideAScore: 'FDA Approved', peptideBScore: 'Research only', notes: 'Tesamorelin is FDA-approved for HIV lipodystrophy. Ipamorelin is not FDA-approved.', winner: 'A' },
      { name: 'Fat Loss Evidence', peptideAScore: 'Strong (visceral fat)', peptideBScore: 'Moderate', notes: 'Tesamorelin has clinical trial data showing visceral fat reduction. Ipamorelin evidence is preclinical.', winner: 'A' },
      { name: 'Mechanism', peptideAScore: 'GHRH analog', peptideBScore: 'Ghrelin mimetic (GHRP)', notes: 'Both stimulate GH release through different pathways. Often combined for synergistic effect.', winner: 'tie' },
      { name: 'Hunger Impact', peptideAScore: 'Minimal', peptideBScore: 'Minimal', notes: 'Neither significantly affects appetite — unlike GHRP-6 or MK-677.', winner: 'tie' },
      { name: 'Cost', peptideAScore: '$200-400/mo', peptideBScore: '$50-100/mo', notes: 'Tesamorelin is more expensive but offers stronger evidence and FDA approval.', winner: 'B' },
    ],
    verdicts: [
      {
        peptide: 'Tesamorelin',
        heading: 'Choose Tesamorelin if...',
        reasons: [
          'Visceral fat reduction is your primary goal',
          'You want an FDA-approved option with clinical data',
          'You can afford the higher cost or have insurance coverage',
        ],
      },
      {
        peptide: 'Ipamorelin',
        heading: 'Choose Ipamorelin if...',
        reasons: [
          'Budget is a priority',
          'Sleep quality and recovery are your main goals',
          'You plan to stack with CJC-1295 for synergistic GH release',
        ],
      },
    ],
    citations: [
      { authors: 'Falutz J, Allas S, et al.', title: 'Metabolic effects of a growth hormone-releasing factor in patients with HIV', journal: 'N Engl J Med', year: 2007, pmid: '17914040', keyFinding: 'Tesamorelin reduced trunk fat by 15% in HIV patients with lipodystrophy, leading to FDA approval.' },
    ],
    faqs: [
      { question: 'Can I get tesamorelin prescribed for weight loss?', answer: 'Tesamorelin is FDA-approved only for HIV-associated lipodystrophy. Some anti-aging clinics prescribe it off-label for visceral fat reduction. Insurance typically only covers the on-label indication.' },
    ],
    relatedComparisons: ['ipamorelin-vs-cjc-1295', 'ipamorelin-cjc-1295-vs-mk-677', 'sermorelin-vs-ipamorelin'],
  },
  // --- NEW COMPARISONS (Phase 4) ---
  {
    slug: 'oral-semaglutide-vs-injectable',
    peptideA: 'semaglutide',
    peptideB: 'semaglutide',
    title: 'Oral vs Injectable Semaglutide: Which Delivery Method Is Better?',
    metaDescription: 'Compare oral semaglutide (Rybelsus) vs injectable semaglutide (Ozempic/Wegovy). Bioavailability, weight loss efficacy, convenience, and cost differences.',
    keyTakeaway: 'Injectable semaglutide produces greater weight loss than oral due to higher bioavailable doses. Oral semaglutide offers needle-free convenience but requires strict fasting protocols.',
    lastUpdated: '2026-02-20',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Weight Loss', peptideAScore: '5-7% (oral 14mg)', peptideBScore: '15-17% (injectable 2.4mg)', notes: 'Injectable semaglutide achieves significantly more weight loss due to higher effective doses.', winner: 'B' },
      { name: 'Administration', peptideAScore: 'Daily oral tablet', peptideBScore: 'Weekly injection', notes: 'Oral requires daily fasting protocol (30 min before food). Injectable is once weekly.', winner: 'tie' },
      { name: 'Bioavailability', peptideAScore: '~1% (SNAC enhancer)', peptideBScore: '~89%', notes: 'Oral bioavailability is extremely low despite the SNAC absorption enhancer.', winner: 'B' },
      { name: 'Convenience', peptideAScore: 'No needles', peptideBScore: 'Once weekly', notes: 'Oral eliminates injection anxiety. But daily fasting requirement adds complexity.', winner: 'A' },
      { name: 'FDA Status', peptideAScore: 'Approved (T2D)', peptideBScore: 'Approved (T2D + obesity)', notes: 'Rybelsus approved for T2D. Higher-dose oral semaglutide for obesity in development.', winner: 'B' },
      { name: 'Cost', peptideAScore: '$900-1,000/mo', peptideBScore: '$1,000-1,350/mo', notes: 'Similar brand-name pricing. Injectable has more compounded options.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'Oral Semaglutide',
        heading: 'Choose Oral if...',
        reasons: [
          'You have severe needle phobia',
          'Your primary goal is blood sugar management (not maximum weight loss)',
          'You can commit to the daily fasting protocol',
        ],
      },
      {
        peptide: 'Injectable Semaglutide',
        heading: 'Choose Injectable if...',
        reasons: [
          'Maximum weight loss is your goal',
          'You prefer weekly dosing over daily',
          'You want access to compounded options at lower cost',
        ],
      },
    ],
    citations: [
      { authors: 'Aroda VR, Rosenstock J, et al.', title: 'PIONEER 1: Oral Semaglutide in Type 2 Diabetes', journal: 'Diabetes Care', year: 2019, pmid: '31530666', keyFinding: 'Oral semaglutide 14mg achieved modest weight loss and A1C reduction vs placebo.' },
    ],
    faqs: [
      { question: 'Will higher-dose oral semaglutide match injectable?', answer: 'Novo Nordisk is developing oral semaglutide 25mg and 50mg doses. Early data from the OASIS trials suggests the higher oral doses may approach injectable efficacy for weight loss, but these are not yet FDA-approved.' },
      { question: 'Can I switch between oral and injectable?', answer: 'Yes, under medical supervision. Your doctor will determine appropriate dose conversion since the oral and injectable doses are not directly equivalent due to bioavailability differences.' },
    ],
    relatedComparisons: ['ozempic-vs-wegovy', 'semaglutide-vs-tirzepatide', 'compounded-vs-brand-semaglutide'],
  },
  {
    slug: 'aod-9604-vs-semaglutide',
    peptideA: 'aod-9604',
    peptideB: 'semaglutide',
    title: 'AOD-9604 vs Semaglutide: Research Peptide vs FDA-Approved GLP-1',
    metaDescription: 'Compare AOD-9604 (HGH fragment for fat loss) vs semaglutide (GLP-1 for weight loss). Mechanisms, evidence levels, cost, and which is right for your goals.',
    keyTakeaway: 'Semaglutide has vastly stronger clinical evidence and FDA approval, producing 15-17% weight loss. AOD-9604 targets localized fat through a different mechanism but lacks robust human data.',
    lastUpdated: '2026-02-01',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Weight Loss', peptideAScore: 'Moderate (localized)', peptideBScore: '15-17% total body weight', notes: 'Semaglutide has gold-standard weight loss data. AOD-9604 targets fat metabolism specifically.', winner: 'B' },
      { name: 'Mechanism', peptideAScore: 'HGH fragment (lipolysis)', peptideBScore: 'GLP-1 receptor agonist', notes: 'Completely different mechanisms. AOD mimics GH fat-burning action. Semaglutide works through appetite and metabolism.', winner: 'tie' },
      { name: 'Evidence Level', peptideAScore: 'Preliminary', peptideBScore: 'Strong (multiple Phase 3)', notes: 'Semaglutide has extensive clinical trial data. AOD-9604 failed in Phase 2b/3 for obesity in 2007.', winner: 'B' },
      { name: 'FDA Status', peptideAScore: 'Research only', peptideBScore: 'FDA Approved', notes: 'Semaglutide is FDA-approved. AOD-9604 is not approved and is available only as a research peptide.', winner: 'B' },
      { name: 'Side Effects', peptideAScore: 'Minimal', peptideBScore: 'GI effects (nausea, etc.)', notes: 'AOD-9604 has fewer reported side effects. Semaglutide commonly causes GI issues during titration.', winner: 'A' },
      { name: 'Cost', peptideAScore: '$30-50/mo', peptideBScore: '$150-1,350/mo', notes: 'AOD-9604 is significantly cheaper. Semaglutide brand-name is expensive; compounded is moderate.', winner: 'A' },
    ],
    verdicts: [
      {
        peptide: 'AOD-9604',
        heading: 'Consider AOD-9604 if...',
        reasons: [
          'You want targeted fat metabolism support at low cost',
          'You prefer minimal side effects over maximum efficacy',
          'You are already lean and want localized fat reduction',
        ],
      },
      {
        peptide: 'Semaglutide',
        heading: 'Choose Semaglutide if...',
        reasons: [
          'You want clinically proven, FDA-approved weight loss',
          'You have significant weight to lose (BMI 27+)',
          'Evidence quality and safety data matter to you',
        ],
      },
    ],
    citations: [
      { authors: 'Heffernan M, Summers RJ, et al.', title: 'The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism', journal: 'Endocrinology', year: 2001, pmid: '11564714', keyFinding: 'AOD-9604 stimulates lipolysis and inhibits lipogenesis in animal models without affecting IGF-1 or blood glucose.' },
    ],
    faqs: [
      { question: 'Why did AOD-9604 fail FDA trials?', answer: 'The Phase 2b/3 trial (2007) did not demonstrate statistically significant weight loss compared to placebo at the doses tested. The research peptide community still uses it based on preclinical data and anecdotal reports, but the clinical trial evidence is weak.' },
    ],
    relatedComparisons: ['mots-c-vs-aod-9604', 'semaglutide-vs-tirzepatide', 'compounded-vs-brand-semaglutide'],
  },
  {
    slug: 'cagrilintide-semaglutide-vs-tirzepatide',
    peptideA: 'cagrilintide',
    peptideB: 'tirzepatide',
    title: 'CagriSema vs Tirzepatide: The 2026 Weight Loss Showdown',
    metaDescription: 'Compare CagriSema (cagrilintide + semaglutide) vs tirzepatide for weight loss. The newest combination therapy vs the dual agonist — mechanisms, trial data, and outlook.',
    keyTakeaway: 'CagriSema (cagrilintide + semaglutide) adds amylin to GLP-1 action, potentially matching or exceeding tirzepatide. Both represent the cutting edge of obesity treatment.',
    lastUpdated: '2026-02-15',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Weight Loss', peptideAScore: '~22-25% (Phase 3 pending)', peptideBScore: '20-26%', notes: 'CagriSema Phase 2 showed ~15.6% in T2D. Full obesity Phase 3 data expected 2026.', winner: 'tie' },
      { name: 'Mechanism', peptideAScore: 'GLP-1 + amylin analog', peptideBScore: 'GLP-1 + GIP dual agonist', notes: 'CagriSema combines two separate peptides. Tirzepatide is a single molecule hitting two receptors.', winner: 'tie' },
      { name: 'FDA Status', peptideAScore: 'Phase 3', peptideBScore: 'Approved', notes: 'Tirzepatide is FDA-approved. CagriSema is in Phase 3 trials (REDEFINE program).', winner: 'B' },
      { name: 'Administration', peptideAScore: 'Weekly (single pen)', peptideBScore: 'Weekly', notes: 'CagriSema combines both drugs in one injection. Same weekly convenience as tirzepatide.', winner: 'tie' },
      { name: 'Satiety Mechanism', peptideAScore: 'GLP-1 + amylin (dual satiety)', peptideBScore: 'GLP-1 + GIP (incretin + metabolic)', notes: 'Different approaches to appetite suppression. Amylin works through different brain regions than GIP.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'CagriSema',
        heading: 'Watch CagriSema if...',
        reasons: [
          'You want the newest dual-mechanism approach (GLP-1 + amylin)',
          'You are interested in clinical trial participation',
          'You want an option from the same company that makes Wegovy (Novo Nordisk)',
        ],
      },
      {
        peptide: 'Tirzepatide',
        heading: 'Choose Tirzepatide if...',
        reasons: [
          'You want an available, FDA-approved option today',
          'Proven 20-26% weight loss data is sufficient for your goals',
          'You prefer a single molecule over a combination product',
        ],
      },
    ],
    citations: [
      { authors: 'Frias JP, Deenadayalan S, et al.', title: 'Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes', journal: 'Lancet', year: 2023, pmid: '37352883', keyFinding: 'CagriSema achieved 15.6% weight loss in T2D at 32 weeks, exceeding semaglutide alone.' },
    ],
    faqs: [
      { question: 'When will CagriSema be available?', answer: 'Novo Nordisk Phase 3 REDEFINE trials are ongoing. If successful, FDA approval could come in late 2026 or 2027. The exact timeline depends on trial results and regulatory review speed.' },
      { question: 'Is CagriSema better than tirzepatide?', answer: 'We will not know until Phase 3 data is available. Phase 2 data in T2D showed strong results but the full obesity program results are pending. Head-to-head comparison is premature.' },
    ],
    relatedComparisons: ['semaglutide-vs-tirzepatide', 'semaglutide-vs-retatrutide', 'semaglutide-vs-tirzepatide-vs-retatrutide'],
  },
  {
    slug: 'semaglutide-vs-tesofensine',
    peptideA: 'semaglutide',
    peptideB: 'tesofensine',
    title: 'Semaglutide vs Tesofensine: GLP-1 vs Triple Reuptake Inhibitor',
    metaDescription: 'Compare semaglutide (GLP-1 agonist) vs tesofensine (dopamine/norepinephrine/serotonin reuptake inhibitor) for weight loss. Completely different mechanisms analyzed.',
    keyTakeaway: 'Semaglutide is FDA-approved with strong evidence. Tesofensine works through brain neurotransmitter reuptake inhibition and showed strong Phase 2 results but stalled in development.',
    lastUpdated: '2026-01-10',
    category: 'glp1-weight-loss',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Weight Loss', peptideAScore: '15-17%', peptideBScore: '12-13% (Phase 2)', notes: 'Both show significant weight loss. Tesofensine Phase 2 data was promising but Phase 3 never completed.', winner: 'A' },
      { name: 'Mechanism', peptideAScore: 'GLP-1 receptor agonist', peptideBScore: 'Triple monoamine reuptake inhibitor', notes: 'Completely different mechanisms. Semaglutide = gut hormone. Tesofensine = brain neurotransmitter.', winner: 'tie' },
      { name: 'FDA Status', peptideAScore: 'FDA Approved', peptideBScore: 'Research only', notes: 'Semaglutide fully approved. Tesofensine never completed Phase 3 trials.', winner: 'A' },
      { name: 'Administration', peptideAScore: 'Weekly injection', peptideBScore: 'Daily oral', notes: 'Tesofensine is oral, which is more convenient. But semaglutide is only once weekly.', winner: 'tie' },
      { name: 'Safety Concerns', peptideAScore: 'GI effects (well-characterized)', peptideBScore: 'CV concerns (heart rate/BP increase)', notes: 'Tesofensine raises heart rate and blood pressure, which stalled its development. Semaglutide GI effects are well-managed.', winner: 'A' },
      { name: 'Cost', peptideAScore: '$150-1,350/mo', peptideBScore: '$50-100/mo (research)', notes: 'Tesofensine available cheaply from research suppliers. Semaglutide brand-name is expensive.', winner: 'B' },
    ],
    verdicts: [
      {
        peptide: 'Semaglutide',
        heading: 'Choose Semaglutide if...',
        reasons: [
          'You want a proven, FDA-approved weight loss medication',
          'Safety and long-term data matter to you',
          'You prefer a well-characterized side effect profile',
        ],
      },
      {
        peptide: 'Tesofensine',
        heading: 'Consider Tesofensine if...',
        reasons: [
          'You cannot tolerate GLP-1 side effects (nausea)',
          'You prefer oral daily dosing',
          'You understand the cardiovascular risk profile and are willing to monitor',
        ],
      },
    ],
    citations: [
      { authors: 'Astrup A, Madsbad S, et al.', title: 'Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients', journal: 'Lancet', year: 2008, pmid: '19012858', keyFinding: 'Tesofensine 0.5mg achieved 12.8% weight loss at 24 weeks in Phase 2, but increased heart rate.' },
    ],
    faqs: [
      { question: 'Why is tesofensine not FDA-approved?', answer: 'Tesofensine Phase 2 showed strong weight loss but also increased heart rate and blood pressure. The developing company (NeuroSearch) ran into financial issues and Phase 3 was never completed. The cardiovascular signal was the primary safety concern.' },
    ],
    relatedComparisons: ['semaglutide-vs-tirzepatide', 'aod-9604-vs-semaglutide', 'compounded-vs-brand-semaglutide'],
  },
  {
    slug: 'bpc-157-vs-ghk-cu',
    peptideA: 'bpc-157',
    peptideB: 'ghk-cu',
    title: 'BPC-157 vs GHK-Cu: Healing vs Anti-Aging Peptide Showdown',
    metaDescription: 'Compare BPC-157 (body protection compound) vs GHK-Cu (copper peptide). Internal healing vs skin rejuvenation — mechanisms, evidence, and which to choose.',
    keyTakeaway: 'BPC-157 is the go-to for internal tissue healing (gut, tendons, joints). GHK-Cu dominates skin rejuvenation and anti-aging. Different targets, complementary when stacked.',
    lastUpdated: '2026-01-15',
    category: 'healing-recovery',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Primary Target', peptideAScore: 'Internal tissue repair', peptideBScore: 'Skin + systemic anti-aging', notes: 'BPC-157 for gut/tendon/joint healing. GHK-Cu for skin, hair, and gene modulation.', winner: 'tie' },
      { name: 'Mechanism', peptideAScore: 'Angiogenesis + nitric oxide', peptideBScore: 'Copper delivery + 4,000+ gene modulation', notes: 'BPC-157 promotes blood vessel formation. GHK-Cu modulates thousands of genes toward a younger expression profile.', winner: 'tie' },
      { name: 'Topical Use', peptideAScore: 'Limited evidence', peptideBScore: 'Primary use case', notes: 'GHK-Cu is widely used in skincare products. BPC-157 topical use has minimal evidence.', winner: 'B' },
      { name: 'Oral Bioavailability', peptideAScore: 'Yes (for gut)', peptideBScore: 'No', notes: 'BPC-157 can be taken orally for GI healing. GHK-Cu requires topical or injection.', winner: 'A' },
      { name: 'Research Level', peptideAScore: 'Moderate (animal)', peptideBScore: 'Moderate (skin + animal)', notes: 'Both lack extensive human clinical trials. GHK-Cu has more human skin data from cosmetic studies.', winner: 'tie' },
      { name: 'Cost', peptideAScore: '$30-60/vial', peptideBScore: '$25-60/vial', notes: 'Similar pricing for injectable forms. GHK-Cu topical serums priced separately.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'BPC-157',
        heading: 'Choose BPC-157 if...',
        reasons: [
          'You have gut issues, tendon injuries, or joint problems',
          'Internal tissue repair is your priority',
          'You want oral dosing for GI healing',
        ],
      },
      {
        peptide: 'GHK-Cu',
        heading: 'Choose GHK-Cu if...',
        reasons: [
          'Skin rejuvenation and anti-aging are your goals',
          'You want a topical option with no injection required',
          'Hair growth or wound healing on the surface is your target',
        ],
      },
    ],
    citations: [
      { authors: 'Pickart L, Vasquez-Soltero JM, Margolina A.', title: 'GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration', journal: 'Biomed Res Int', year: 2015, pmid: '25861625', keyFinding: 'GHK-Cu modulates 4,000+ genes and promotes tissue remodeling, collagen synthesis, and anti-inflammatory responses.' },
      { authors: 'Sikiric P, Rucman R, et al.', title: 'Brain-gut Axis and Pentadecapeptide BPC 157', journal: 'Curr Neuropharmacol', year: 2016, pmid: '26830964', keyFinding: 'BPC-157 promotes tissue repair through angiogenesis, nitric oxide pathways, and growth factor modulation.' },
    ],
    faqs: [
      { question: 'Can I combine BPC-157 and GHK-Cu?', answer: 'Yes. They target completely different systems with no known interactions. BPC-157 for internal healing and GHK-Cu for skin/anti-aging is a common complementary stack.' },
    ],
    relatedComparisons: ['bpc-157-vs-tb-500', 'ghk-cu-vs-bpc-157', 'ghk-cu-vs-epitalon'],
  },
  {
    slug: 'tb-500-vs-thymosin-beta-4',
    peptideA: 'tb-500',
    peptideB: 'thymosin-beta-4',
    title: 'TB-500 vs Thymosin Beta-4: Fragment vs Full Protein Explained',
    metaDescription: 'TB-500 is a synthetic fragment of thymosin beta-4. Compare the fragment vs the full protein — mechanisms, availability, cost, and which one to choose.',
    keyTakeaway: 'TB-500 IS a fragment of thymosin beta-4, not a separate compound. TB-500 is more affordable and widely available. Full thymosin beta-4 is the complete protein with broader research backing.',
    lastUpdated: '2026-01-10',
    category: 'healing-recovery',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Relationship', peptideAScore: 'Fragment (17-23 region)', peptideBScore: 'Full 43-amino-acid protein', notes: 'TB-500 is the active fragment of thymosin beta-4. It contains the actin-binding region responsible for healing effects.', winner: 'tie' },
      { name: 'Mechanism', peptideAScore: 'Actin sequestration (active region)', peptideBScore: 'Actin sequestration + additional domains', notes: 'Both work through actin regulation. Full TB4 has additional functional regions that may contribute to effects.', winner: 'B' },
      { name: 'Research', peptideAScore: 'Limited (mostly extrapolated)', peptideBScore: 'More extensive', notes: 'Most published research uses full thymosin beta-4. TB-500 effects are largely extrapolated from TB4 studies.', winner: 'B' },
      { name: 'Availability', peptideAScore: 'Widely available (research)', peptideBScore: 'Less common, more expensive', notes: 'TB-500 is more commonly available from research peptide suppliers. Full TB4 is harder to source.', winner: 'A' },
      { name: 'Cost', peptideAScore: '$40-80/vial', peptideBScore: '$80-200/vial', notes: 'TB-500 is significantly cheaper due to simpler synthesis (shorter peptide chain).', winner: 'A' },
      { name: 'Practical Equivalence', peptideAScore: 'Likely similar for healing', peptideBScore: 'Potentially broader effects', notes: 'For tissue repair purposes, most users report similar results. Full TB4 may have additional immune benefits.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'TB-500',
        heading: 'Choose TB-500 if...',
        reasons: [
          'Budget matters (2-3x cheaper)',
          'Tissue repair and injury recovery are your primary goals',
          'You want the most widely available option',
        ],
      },
      {
        peptide: 'Thymosin Beta-4',
        heading: 'Choose full TB4 if...',
        reasons: [
          'You want the full protein with all functional domains',
          'Immune modulation is part of your goal',
          'You can source pharmaceutical-grade full-length TB4',
        ],
      },
    ],
    citations: [
      { authors: 'Goldstein AL, Hannappel E, et al.', title: 'Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues', journal: 'Trends Mol Med', year: 2005, pmid: '16087402', keyFinding: 'Thymosin beta-4 promotes wound healing, angiogenesis, and anti-inflammation through actin-sequestering and cell migration.' },
    ],
    faqs: [
      { question: 'Is TB-500 the same as thymosin beta-4?', answer: 'Not exactly. TB-500 is a synthetic peptide fragment corresponding to amino acids 17-23 of thymosin beta-4. It contains the active actin-binding sequence but is not the complete protein. Most healing effects are attributed to this region, which is why TB-500 is used as a more affordable alternative.' },
    ],
    relatedComparisons: ['bpc-157-vs-tb-500', 'pentadecapeptide-bpc-157-vs-ghk-cu-vs-tb-500'],
  },
  {
    slug: 'sermorelin-vs-ipamorelin',
    peptideA: 'sermorelin',
    peptideB: 'ipamorelin',
    title: 'Sermorelin vs Ipamorelin: Two Paths to Growth Hormone Release',
    metaDescription: 'Compare sermorelin (GHRH analog) vs ipamorelin (GHRP/ghrelin mimetic). Two different mechanisms for stimulating natural growth hormone release.',
    keyTakeaway: 'Sermorelin and ipamorelin stimulate GH through different pathways — GHRH vs ghrelin receptors. Ipamorelin is more selective with fewer side effects. They are commonly stacked rather than used as alternatives.',
    lastUpdated: '2026-01-15',
    category: 'gh-secretagogue',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Mechanism', peptideAScore: 'GHRH analog (GRF 1-29)', peptideBScore: 'Ghrelin mimetic (GHRP)', notes: 'Sermorelin mimics GHRH to stimulate pituitary GH release. Ipamorelin acts on the ghrelin receptor.', winner: 'tie' },
      { name: 'Selectivity', peptideAScore: 'Moderate', peptideBScore: 'High (most selective GHRP)', notes: 'Ipamorelin does not raise cortisol or prolactin. Sermorelin is also clean but less studied for selectivity.', winner: 'B' },
      { name: 'FDA History', peptideAScore: 'Previously FDA-approved', peptideBScore: 'Research only', notes: 'Sermorelin was FDA-approved (Geref) but discontinued for commercial reasons. Ipamorelin never approved.', winner: 'A' },
      { name: 'Half-Life', peptideAScore: '~10-20 minutes', peptideBScore: '~2 hours', notes: 'Ipamorelin has a longer effective window per dose.', winner: 'B' },
      { name: 'Best Stacking Partner', peptideAScore: 'GHRP (ipamorelin)', peptideBScore: 'GHRH (CJC-1295 or sermorelin)', notes: 'Both work best when stacked with the complementary pathway — GHRH + GHRP synergy.', winner: 'tie' },
      { name: 'Cost', peptideAScore: '$50-100/mo', peptideBScore: '$50-100/mo', notes: 'Similar pricing from research peptide suppliers and anti-aging clinics.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'Sermorelin',
        heading: 'Choose Sermorelin if...',
        reasons: [
          'You want a peptide with prior FDA-approval history',
          'You prefer the GHRH pathway for GH stimulation',
          'Your anti-aging clinic offers it as a primary option',
        ],
      },
      {
        peptide: 'Ipamorelin',
        heading: 'Choose Ipamorelin if...',
        reasons: [
          'You want the most selective GHRP (no cortisol/prolactin effects)',
          'Sleep quality and recovery are primary goals',
          'You plan to stack with CJC-1295 for maximum synergy',
        ],
      },
    ],
    citations: [
      { authors: 'Walker RF', title: 'Sermorelin: A better approach to management of adult-onset growth hormone insufficiency?', journal: 'Clin Interv Aging', year: 2006, pmid: '18046909', keyFinding: 'Sermorelin stimulates natural GH production and maintains physiological feedback mechanisms, unlike exogenous GH.' },
    ],
    faqs: [
      { question: 'Can I take sermorelin and ipamorelin together?', answer: 'Yes, this is a popular stack. Sermorelin (GHRH) and ipamorelin (GHRP) stimulate GH through complementary pathways, producing synergistic release. Many anti-aging clinics prescribe this combination.' },
    ],
    relatedComparisons: ['ipamorelin-vs-cjc-1295', 'tesamorelin-vs-ipamorelin', 'ipamorelin-cjc-1295-vs-mk-677'],
  },
  {
    slug: 'ghrp-2-vs-ghrp-6-vs-ipamorelin',
    peptideA: 'ghrp-2',
    peptideB: 'ghrp-6',
    peptideC: 'ipamorelin',
    title: 'GHRP-2 vs GHRP-6 vs Ipamorelin: Which GHRP Is Best?',
    metaDescription: 'Compare three popular growth hormone releasing peptides: GHRP-2, GHRP-6, and ipamorelin. GH release potency, hunger effects, side effects, and selectivity.',
    keyTakeaway: 'Ipamorelin is the most selective with the cleanest side effect profile. GHRP-6 causes the most hunger. GHRP-2 is a middle ground between potency and selectivity.',
    lastUpdated: '2026-01-10',
    category: 'gh-secretagogue',
    hasEditorialContent: true,
    dimensions: [
      { name: 'GH Release Potency', peptideAScore: 'High', peptideBScore: 'High', peptideCScore: 'Moderate-High', notes: 'GHRP-2 and GHRP-6 produce stronger acute GH spikes. Ipamorelin is slightly less potent but much cleaner.', winner: 'A' },
      { name: 'Hunger Increase', peptideAScore: 'Moderate', peptideBScore: 'Severe', peptideCScore: 'None', notes: 'GHRP-6 causes intense hunger via strong ghrelin activation. GHRP-2 mild hunger. Ipamorelin none.', winner: 'C' },
      { name: 'Cortisol Impact', peptideAScore: 'Slight increase', peptideBScore: 'Moderate increase', peptideCScore: 'No increase', notes: 'Only ipamorelin avoids raising cortisol levels.', winner: 'C' },
      { name: 'Prolactin Impact', peptideAScore: 'Slight increase', peptideBScore: 'Slight increase', peptideCScore: 'No increase', notes: 'Ipamorelin is the only GHRP that does not elevate prolactin.', winner: 'C' },
      { name: 'Selectivity', peptideAScore: 'Moderate', peptideBScore: 'Low', peptideCScore: 'High', notes: 'Ipamorelin is the most selective GHRP — GH release without hormonal side effects.', winner: 'C' },
      { name: 'Best For', peptideAScore: 'Balanced GH + some appetite', peptideBScore: 'Max GH + appetite for bulking', peptideCScore: 'Clean GH for recovery/sleep', notes: 'GHRP-6 for hardgainers. GHRP-2 for balanced use. Ipamorelin for recovery and anti-aging.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'GHRP-2',
        heading: 'Choose GHRP-2 if...',
        reasons: [
          'You want strong GH release with manageable side effects',
          'Mild appetite increase is acceptable',
          'You want a middle-ground between potency and selectivity',
        ],
      },
      {
        peptide: 'GHRP-6',
        heading: 'Choose GHRP-6 if...',
        reasons: [
          'You want maximum GH release and are bulking',
          'Appetite stimulation is a feature (underweight or difficulty eating)',
          'You accept cortisol and prolactin increases',
        ],
      },
      {
        peptide: 'Ipamorelin',
        heading: 'Choose Ipamorelin if...',
        reasons: [
          'You want the cleanest GHRP with zero cortisol/prolactin impact',
          'Sleep quality and recovery are primary goals',
          'You want to avoid appetite stimulation',
        ],
      },
    ],
    citations: [
      { authors: 'Raun K, Hansen BS, et al.', title: 'Ipamorelin, the first selective growth hormone secretagogue', journal: 'Eur J Endocrinol', year: 1998, pmid: '9784065', keyFinding: 'Ipamorelin selectively stimulates GH without affecting ACTH, cortisol, prolactin, or FSH/LH levels.' },
    ],
    faqs: [
      { question: 'Which GHRP is best for beginners?', answer: 'Ipamorelin is the most recommended GHRP for beginners due to its clean side effect profile — no hunger spikes, no cortisol or prolactin increases, and smooth GH release. Start with ipamorelin and only consider GHRP-2 or GHRP-6 if you need more potency for specific goals.' },
    ],
    relatedComparisons: ['ipamorelin-vs-cjc-1295', 'sermorelin-vs-ipamorelin', 'ipamorelin-cjc-1295-vs-mk-677'],
  },
  {
    slug: 'ghk-cu-vs-epitalon',
    peptideA: 'ghk-cu',
    peptideB: 'epitalon',
    title: 'GHK-Cu vs Epitalon: Copper Peptide vs Telomerase Activator',
    metaDescription: 'Compare GHK-Cu (copper peptide for skin and gene modulation) vs epitalon (telomerase activator for cellular aging). Two different approaches to anti-aging.',
    keyTakeaway: 'GHK-Cu works from the outside in — skin, collagen, gene expression. Epitalon works from the inside out — telomere extension and pineal gland function. Different anti-aging targets, often used together.',
    lastUpdated: '2026-01-10',
    category: 'anti-aging',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Anti-Aging Mechanism', peptideAScore: 'Gene modulation + collagen', peptideBScore: 'Telomerase activation', notes: 'GHK-Cu modulates 4,000+ genes toward youthful patterns. Epitalon activates telomerase to extend telomeres.', winner: 'tie' },
      { name: 'Primary Benefits', peptideAScore: 'Skin, hair, wound healing', peptideBScore: 'Cellular longevity, sleep, melatonin', notes: 'GHK-Cu has visible cosmetic effects. Epitalon works at the cellular level with less visible short-term results.', winner: 'tie' },
      { name: 'Research Level', peptideAScore: 'Moderate (human skin data)', peptideBScore: 'Preliminary (animal + Russian studies)', notes: 'GHK-Cu has cosmetic industry data. Epitalon research largely from Russian institutes (Khavinson).', winner: 'A' },
      { name: 'Administration', peptideAScore: 'Topical, SubQ, or IV', peptideBScore: 'SubQ (10-day cycles)', notes: 'GHK-Cu topical is the most common use. Epitalon requires injection in 10-day cycles, 2-3x/year.', winner: 'A' },
      { name: 'Side Effects', peptideAScore: 'Very minimal', peptideBScore: 'Very minimal', notes: 'Both well-tolerated with minimal reported side effects.', winner: 'tie' },
      { name: 'Cost', peptideAScore: '$25-60/vial', peptideBScore: '$40-80/vial', notes: 'Similar pricing. GHK-Cu topical serums can be more expensive but more accessible.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'GHK-Cu',
        heading: 'Choose GHK-Cu if...',
        reasons: [
          'Visible anti-aging results matter (skin, hair, collagen)',
          'You want a topical option that avoids injections',
          'You want broader research backing (cosmetic + preclinical)',
        ],
      },
      {
        peptide: 'Epitalon',
        heading: 'Choose Epitalon if...',
        reasons: [
          'Cellular-level longevity is your goal (telomere extension)',
          'You want to support melatonin production and sleep',
          'You are building a comprehensive anti-aging protocol',
        ],
      },
    ],
    citations: [
      { authors: 'Pickart L, Vasquez-Soltero JM, Margolina A.', title: 'GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration', journal: 'Biomed Res Int', year: 2015, pmid: '25861625', keyFinding: 'GHK-Cu modulates 4,000+ genes involved in tissue remodeling, anti-inflammatory responses, and stem cell activity.' },
      { authors: 'Khavinson VK, Bondarev IE, Butyugov AA.', title: 'Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells', journal: 'Bull Exp Biol Med', year: 2003, pmid: '14612753', keyFinding: 'Epitalon induced telomerase activity and increased telomere length in human pulmonary fibroblasts.' },
    ],
    faqs: [
      { question: 'Can I use both GHK-Cu and epitalon?', answer: 'Yes. They target completely different aging mechanisms. GHK-Cu for surface-level rejuvenation and gene modulation. Epitalon for cellular-level longevity. Many anti-aging protocols include both.' },
    ],
    relatedComparisons: ['ghk-cu-vs-bpc-157', 'bpc-157-vs-ghk-cu', 'pentadecapeptide-bpc-157-vs-ghk-cu-vs-tb-500'],
  },
  {
    slug: 'semax-vs-selank',
    peptideA: 'semax',
    peptideB: 'selank',
    title: 'Semax vs Selank: Nootropic Peptides for Brain Performance',
    metaDescription: 'Compare semax (ACTH fragment for focus and cognition) vs selank (tuftsin analog for anxiety and mood). Two Russian nootropic peptides with different targets.',
    keyTakeaway: 'Semax enhances focus, cognition, and BDNF. Selank reduces anxiety and improves mood through GABA modulation. One is a stimulating nootropic; the other is a calming anxiolytic.',
    lastUpdated: '2026-01-10',
    category: 'nootropic',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Primary Effect', peptideAScore: 'Cognitive enhancement + focus', peptideBScore: 'Anxiety reduction + mood', notes: 'Semax is stimulating and focus-enhancing. Selank is calming and anxiolytic.', winner: 'tie' },
      { name: 'Mechanism', peptideAScore: 'ACTH(4-10) fragment + BDNF boost', peptideBScore: 'Tuftsin analog + GABA modulation', notes: 'Semax increases BDNF and dopamine. Selank modulates GABA and enkephalins for anti-anxiety effects.', winner: 'tie' },
      { name: 'Administration', peptideAScore: 'Intranasal drops', peptideBScore: 'Intranasal drops', notes: 'Both administered as nasal drops for rapid brain delivery. No injection needed.', winner: 'tie' },
      { name: 'Energy Effect', peptideAScore: 'Stimulating', peptideBScore: 'Calming (not sedating)', notes: 'Semax can feel energizing/focusing. Selank reduces anxiety without causing drowsiness.', winner: 'tie' },
      { name: 'Research', peptideAScore: 'Moderate (Russian clinical)', peptideBScore: 'Moderate (Russian clinical)', notes: 'Both approved for medical use in Russia. Limited Western clinical trials.', winner: 'tie' },
      { name: 'Cost', peptideAScore: '$30-60/vial', peptideBScore: '$30-60/vial', notes: 'Similar pricing. Both available from research peptide suppliers.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'Semax',
        heading: 'Choose Semax if...',
        reasons: [
          'You want enhanced focus, learning, and cognitive performance',
          'You respond well to stimulating nootropics',
          'BDNF elevation and neuroprotection are your goals',
        ],
      },
      {
        peptide: 'Selank',
        heading: 'Choose Selank if...',
        reasons: [
          'Anxiety reduction is your primary goal',
          'You want mood stabilization without sedation',
          'You prefer calming nootropics over stimulating ones',
        ],
      },
    ],
    citations: [
      { authors: 'Eremin KO, Kudrin VS, et al.', title: 'Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems', journal: 'Bull Exp Biol Med', year: 2005, pmid: '16027831', keyFinding: 'Semax activates dopamine and serotonin systems in the brain, enhancing cognitive function and neuroprotection.' },
      { authors: 'Zozulya AA, Gabaeva MV, et al.', title: 'Selank: An anxiolytic peptide', journal: 'Bull Exp Biol Med', year: 2008, pmid: '18726017', keyFinding: 'Selank demonstrates anxiolytic activity comparable to benzodiazepines but without sedation or dependence risk.' },
    ],
    faqs: [
      { question: 'Can I take semax and selank together?', answer: 'Yes. Many users stack both — semax for cognitive enhancement and selank for anxiety management. They work through different pathways and complement each other. Some find the combination provides focused calm.' },
      { question: 'Are these peptides addictive?', answer: 'Neither semax nor selank shows addictive potential in available research. Unlike benzodiazepines, selank does not appear to cause physical dependence. Both are considered safe for regular use based on Russian clinical data.' },
    ],
    relatedComparisons: [],
  },
  {
    slug: 'melanotan-ii-vs-pt-141',
    peptideA: 'melanotan-ii',
    peptideB: 'pt-141',
    title: 'Melanotan II vs PT-141: Tanning Peptide vs Sexual Health Treatment',
    metaDescription: 'Compare melanotan II (tanning + libido) vs PT-141/bremelanotide (FDA-approved for HSDD). Same origin, different applications — what you need to know.',
    keyTakeaway: 'PT-141 is an FDA-approved, targeted sexual function treatment derived from melanotan II. MT-II is a broader research peptide that affects both melanogenesis (tanning) and libido but is not FDA-approved.',
    lastUpdated: '2026-01-10',
    category: 'sexual-health',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Primary Use', peptideAScore: 'Tanning + libido (off-label)', peptideBScore: 'Sexual dysfunction (FDA-approved)', notes: 'MT-II used mainly for tanning with libido as a side benefit. PT-141 is specifically designed for sexual function.', winner: 'tie' },
      { name: 'FDA Status', peptideAScore: 'Research only', peptideBScore: 'FDA Approved (Vyleesi)', notes: 'PT-141 (bremelanotide) is FDA-approved as Vyleesi for HSDD in premenopausal women. MT-II is not approved.', winner: 'B' },
      { name: 'Melanogenesis', peptideAScore: 'Strong tanning effect', peptideBScore: 'Minimal', notes: 'MT-II strongly activates MC1R for skin darkening. PT-141 was designed to target MC3R/MC4R (sexual) over MC1R.', winner: 'A' },
      { name: 'Side Effects', peptideAScore: 'Nausea, flushing, moles', peptideBScore: 'Nausea, flushing (less tanning)', notes: 'MT-II causes more skin changes (new moles, darkening). PT-141 side effects are mostly nausea and flushing.', winner: 'B' },
      { name: 'Administration', peptideAScore: 'SubQ injection', peptideBScore: 'SubQ injection (autoinjector)', notes: 'PT-141 as Vyleesi comes in a pre-filled autoinjector. MT-II requires vial reconstitution.', winner: 'B' },
      { name: 'Cost', peptideAScore: '$20-40/vial (research)', peptideBScore: '$800-1,000/dose (brand)', notes: 'MT-II is very cheap from research suppliers. Brand-name Vyleesi is expensive. Compounded PT-141 is moderate.', winner: 'A' },
    ],
    verdicts: [
      {
        peptide: 'Melanotan II',
        heading: 'Consider Melanotan II if...',
        reasons: [
          'Tanning is your primary goal with libido as a secondary benefit',
          'You are comfortable with research-grade peptides',
          'Budget is a factor',
        ],
      },
      {
        peptide: 'PT-141',
        heading: 'Choose PT-141 if...',
        reasons: [
          'Sexual function is your primary goal',
          'You want an FDA-approved option (Vyleesi)',
          'You prefer targeted action without tanning effects',
        ],
      },
    ],
    citations: [
      { authors: 'Kingsberg SA, Clayton AH, et al.', title: 'Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder', journal: 'Obstet Gynecol', year: 2019, pmid: '31135760', keyFinding: 'Bremelanotide (PT-141) significantly improved sexual desire and reduced distress in premenopausal women with HSDD.' },
    ],
    faqs: [
      { question: 'Is PT-141 derived from melanotan II?', answer: 'Yes. PT-141 (bremelanotide) was developed from melanotan II research. Scientists noticed MT-II sexual function effects and engineered PT-141 to target those receptors specifically while minimizing the tanning/melanogenesis effects.' },
      { question: 'Does melanotan II increase skin cancer risk?', answer: 'The mole changes caused by MT-II are a safety concern. New nevi (moles) or darkening of existing moles have been reported. While a direct cancer link has not been established, dermatologists advise caution and regular skin checks for MT-II users.' },
    ],
    relatedComparisons: [],
  },
  {
    slug: 'pentadecapeptide-bpc-157-vs-ghk-cu-vs-tb-500',
    peptideA: 'bpc-157',
    peptideB: 'ghk-cu',
    peptideC: 'tb-500',
    title: 'BPC-157 vs GHK-Cu vs TB-500: The Complete Healing Peptide Comparison',
    metaDescription: 'Compare three popular healing and recovery peptides: BPC-157 (body protection), GHK-Cu (copper peptide), and TB-500 (thymosin beta-4). Side-by-side analysis.',
    keyTakeaway: 'Three peptides, three targets: BPC-157 for gut and localized tendon/joint healing, GHK-Cu for skin and anti-aging, TB-500 for systemic tissue repair and cardiac healing. Most effective when combined strategically.',
    lastUpdated: '2026-01-15',
    category: 'cross-category',
    hasEditorialContent: true,
    dimensions: [
      { name: 'Primary Target', peptideAScore: 'Gut + tendons + joints', peptideBScore: 'Skin + anti-aging', peptideCScore: 'Systemic tissue repair', notes: 'Each peptide excels in a different healing domain. Minimal overlap in primary targets.', winner: 'tie' },
      { name: 'Mechanism', peptideAScore: 'Angiogenesis + NO pathway', peptideBScore: 'Gene modulation + copper', peptideCScore: 'Actin regulation + cell migration', notes: 'Three completely different mechanisms — all complementary for healing.', winner: 'tie' },
      { name: 'Oral Option', peptideAScore: 'Yes (gut healing)', peptideBScore: 'Topical (skin)', peptideCScore: 'Injection only', notes: 'BPC-157 has oral bioavailability. GHK-Cu works topically. TB-500 requires SubQ injection.', winner: 'tie' },
      { name: 'Research Level', peptideAScore: 'Moderate (animal)', peptideBScore: 'Moderate (skin + animal)', peptideCScore: 'Moderate (animal)', notes: 'All three have substantial preclinical data but limited human clinical trials.', winner: 'tie' },
      { name: 'Side Effects', peptideAScore: 'Minimal', peptideBScore: 'Minimal', peptideCScore: 'Minimal (head rush)', notes: 'All three are well-tolerated. TB-500 occasionally causes temporary head rush or lightheadedness.', winner: 'tie' },
      { name: 'Cost per Cycle', peptideAScore: '$30-60', peptideBScore: '$25-60', peptideCScore: '$40-80', notes: 'All affordable. Running all three is still cheaper than most pharmaceutical options.', winner: 'tie' },
    ],
    verdicts: [
      {
        peptide: 'BPC-157',
        heading: 'Choose BPC-157 if...',
        reasons: ['Gut healing or localized injury is your priority', 'You want oral dosing for GI issues', 'Tendon or joint recovery is the goal'],
      },
      {
        peptide: 'GHK-Cu',
        heading: 'Choose GHK-Cu if...',
        reasons: ['Skin rejuvenation and anti-aging are your goals', 'You want a topical-first approach', 'Hair growth or wound healing on the surface'],
      },
      {
        peptide: 'TB-500',
        heading: 'Choose TB-500 if...',
        reasons: ['You need systemic tissue repair across multiple areas', 'Cardiac or cardiovascular healing is relevant', 'You want to reduce inflammation system-wide'],
      },
    ],
    citations: [
      { authors: 'Sikiric P, Rucman R, et al.', title: 'Brain-gut Axis and Pentadecapeptide BPC 157', journal: 'Curr Neuropharmacol', year: 2016, pmid: '26830964', keyFinding: 'BPC-157 promotes tissue repair through angiogenesis and growth factor modulation across gut-brain axis.' },
      { authors: 'Pickart L, Vasquez-Soltero JM, Margolina A.', title: 'GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration', journal: 'Biomed Res Int', year: 2015, pmid: '25861625', keyFinding: 'GHK-Cu modulates 4,000+ genes promoting tissue remodeling and anti-inflammatory responses.' },
      { authors: 'Sosne G, Qiu P, et al.', title: 'Thymosin beta 4 and the eye', journal: 'Ann N Y Acad Sci', year: 2012, pmid: '23130423', keyFinding: 'TB-500 promotes wound healing through actin regulation, cell migration, and anti-inflammatory pathways.' },
    ],
    faqs: [
      { question: 'Should I take all three together?', answer: 'You can, but most people choose based on their primary goal. For comprehensive healing (e.g., post-surgery or complex injury), stacking all three provides complementary mechanisms. For targeted goals, pick the one that matches: gut=BPC-157, skin=GHK-Cu, systemic=TB-500.' },
      { question: 'What is the best order to try them?', answer: 'Start with the one that matches your primary goal. BPC-157 is the most commonly used first due to its versatility and oral option. Add TB-500 if systemic healing is needed. GHK-Cu can be used topically at any time alongside the others.' },
    ],
    relatedComparisons: ['bpc-157-vs-tb-500', 'ghk-cu-vs-bpc-157', 'bpc-157-vs-ghk-cu'],
  },
]

export function getComparison(slug: string): Comparison | undefined {
  return comparisons.find((c) => c.slug === slug)
}

export function getComparisonsByPeptide(peptideSlug: string): Comparison[] {
  return comparisons.filter(
    (c) => c.peptideA === peptideSlug || c.peptideB === peptideSlug || c.peptideC === peptideSlug
  )
}

export function getAllComparisonSlugs(): string[] {
  return comparisons.map((c) => c.slug)
}

export function getComparisonsByCategory(category: ComparisonCategory): Comparison[] {
  return comparisons.filter((c) => c.category === category)
}

export function findComparisonByPeptides(slugA: string, slugB: string): Comparison | undefined {
  return comparisons.find(
    (c) =>
      (c.peptideA === slugA && c.peptideB === slugB) ||
      (c.peptideA === slugB && c.peptideB === slugA) ||
      (c.peptideA === slugA && c.peptideC === slugB) ||
      (c.peptideA === slugB && c.peptideC === slugA) ||
      (c.peptideB === slugA && c.peptideC === slugB) ||
      (c.peptideB === slugB && c.peptideC === slugA)
  )
}

export function getRelatedComparisons(slug: string): Comparison[] {
  const comparison = getComparison(slug)
  if (!comparison) return []
  return comparison.relatedComparisons
    .map((s) => getComparison(s))
    .filter((c): c is Comparison => c !== undefined)
}
